<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Invest</journal-id><journal-id journal-id-type="pmc-domain-id">120</journal-id><journal-id journal-id-type="pmc-domain">jcinvest</journal-id><journal-id journal-id-type="publisher-id">J Clin Invest</journal-id><journal-title-group><journal-title>The Journal of Clinical Investigation</journal-title></journal-title-group><issn pub-type="ppub">0021-9738</issn><issn pub-type="epub">1558-8238</issn><publisher><publisher-name>American Society for Clinical Investigation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10836812</article-id><article-id pub-id-type="pmcid-ver">PMC10836812.1</article-id><article-id pub-id-type="pmcaid">10836812</article-id><article-id pub-id-type="pmcaiid">10836812</article-id><article-id pub-id-type="pmid">38299591</article-id><article-id pub-id-type="doi">10.1172/JCI176345</article-id><article-id pub-id-type="publisher-id">176345</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Alcohol-associated liver disease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0001-9840-2013</contrib-id><name name-style="western"><surname>Mackowiak</surname><given-names initials="B">Bryan</given-names></name><email>bryan.mackowiak@nih.gov</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fu</surname><given-names initials="Y">Yaojie</given-names></name><email>yaojie.fu@nih.gov</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maccioni</surname><given-names initials="L">Luca</given-names></name><email>luca.maccioni@nih.gov</email></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Gao</surname><given-names initials="B">Bin</given-names></name><email>bgao@mail.nih.gov</email></contrib></contrib-group><aff>Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, Maryland, USA.</aff><author-notes><corresp>Address correspondence to: Bin Gao, Laboratory of Liver Diseases, NIAAA/NIH, Bethesda, Maryland, 20892, USA. Email: <email>bgao@mail.nih.gov</email>.</corresp><fn><p><bold>Authorship note:</bold> BM and YF contributed equally to this work.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2024-02-01T12:00:00-0500"><day>1</day><month>2</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic" iso-8601-date="2024-02-01T12:00:00-0500"><day>1</day><month>2</month><year>2024</year></pub-date><volume>134</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">454996</issue-id><elocation-id>e176345</elocation-id><pub-history><event event-type="pmc-release"><date><day>01</day><month>02</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>03</day><month>02</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-22 17:25:33.850"><day>22</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 Mackowiak et al.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Mackowiak et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jci-134-176345.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.jci.org/articles/view/176345">This article is available online at https://www.jci.org/articles/view/176345</self-uri><abstract><p>Alcohol-associated liver disease (ALD) is a major cause of chronic liver disease worldwide, and comprises a spectrum of several different disorders, including simple steatosis, steatohepatitis, cirrhosis, and superimposed hepatocellular carcinoma. Although tremendous progress has been made in the field of ALD over the last 20 years, the pathogenesis of ALD remains obscure, and there are currently no FDA-approved drugs for the treatment of ALD. In this Review, we discuss new insights into the pathogenesis and therapeutic targets of ALD, utilizing the study of multiomics and other cutting-edge approaches. The potential translation of these studies into clinical practice and therapy is deliberated. We also discuss preclinical models of ALD, interplay of ALD and metabolic dysfunction, alcohol-associated liver cancer, the heterogeneity of ALD, and some potential translational research prospects for ALD.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Alcohol-associated liver disease (ALD), which replaces the former name &#8220;alcoholic liver disease&#8221; to avoid the use of the stigmatizing word &#8220;alcoholic,&#8221; is one of most common chronic liver diseases worldwide, accounting for approximately 50% of cirrhosis in the USA (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B3" ref-type="bibr">3</xref>). ALD includes an array of liver disorders, ranging from simple steatosis to more severe forms of pathological liver changes, including alcohol-associated steatohepatitis (ASH), cirrhosis, and hepatocellular carcinoma (HCC) (<xref rid="B4" ref-type="bibr">4</xref>) (<xref rid="F1" ref-type="fig">Figure 1</xref>). In addition, patients with underlying ALD and excessive alcohol intake may develop acute alcohol-associated hepatitis (AH), an acute-on-chronic liver injury with prominent cholestasis that causes the typical clinical syndrome jaundice (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>).</p><p>Alcohol is mainly absorbed in the small intestine and metabolized by the liver and other organs (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>), leading to disruption of liver metabolic homeostasis and forming the basis for ALD. Alcohol-associated steatotic liver, which replaces the former name &#8220;alcoholic fatty liver,&#8221; develops in more than 90% of individuals who are heavy drinkers and is characterized by fat accumulation in hepatocytes. Multiple mechanisms contribute to steatosis, including disruption of mitochondrial fatty acid &#946;-oxidation, migration of lipids to the liver from extrahepatic organs, and alteration of lipid metabolism&#8211;associated transcription factors (<xref rid="B4" ref-type="bibr">4</xref>). ASH is a histologic diagnosis characterized by significant steatosis, inflammatory cell infiltration, chicken wire&#8211;like fibrosis, and hepatocyte ballooning, often with the formation of Mallory-Denk bodies. Patients with ASH progress to cirrhosis in 8%&#8211;20% of cases and patients with alcohol-associated cirrhosis progress to HCC in 3%&#8211;10% of cases. Diagnosis of AH is based on clinical presentation, including jaundice, right upper quadrant abdominal pain, fever, elevated serum bilirubin (&gt;3 mg/dL), mildly elevated aspartate aminotransferase (AST) levels (&gt;50 but &lt;400 IU/L), and an AST/alanine aminotransferase (AST/ALT) ratio of &gt;1.5 (<xref rid="B5" ref-type="bibr">5</xref>). In the clinic, the severe form of AH (sAH) has high short-term mortality and is typically referred to as AH, although moderate AH commonly exists (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). There are still no FDA-approved drugs for sAH treatment, and clinical management of sAH involves treatment with oral corticosteroids (<xref rid="B6" ref-type="bibr">6</xref>). Importantly, patients who do not respond to corticosteroid treatment benefit from early liver transplantation (<xref rid="B11" ref-type="bibr">11</xref>). Most patients with mild-to-moderate ALD can recover after cessation of alcohol drinking (<xref rid="B6" ref-type="bibr">6</xref>). In addition, the most important determinant of survival in advanced ALD is whether the patient stops alcohol consumption, and, therefore, pharmacotherapy for alcohol use disorder (AUD) provides survival benefits in alcohol-associated cirrhosis (<xref rid="B12" ref-type="bibr">12</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>). The pathogenesis and clinical management of ALD have been recently summarized in numerous reviews (<xref rid="B4" ref-type="bibr">4</xref>&#8211;<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B15" ref-type="bibr">15</xref>&#8211;<xref rid="B18" ref-type="bibr">18</xref>). In the current Review, we focus on several newly identified mechanisms (including organ crosstalk) that play key roles in ALD progression (<xref rid="F2" ref-type="fig">Figure 2</xref>) and may lead to the discovery of therapeutic targets for sAH (<xref rid="T1" ref-type="table">Table 1</xref>). Recent advances in multiomics and other cutting-edge technologies have been actively applied in the field of ALD, especially sAH, which are briefly summarized. We also point out understudied areas in the ALD field, including alcohol-associated HCC (A-HCC), ALD heterogeneity, and differences in alcohol metabolism and ALD in individuals in Eastern and Western countries.</p></sec><sec><title>Pathogenesis and therapeutic targets of ALD</title><sec><title>Hepatocyte death and regeneration.</title><p>Hepatocyte ballooning, degeneration, and acidophil bodies are the typic histologic features of hepatocyte injury in ASH, while severe ALD, including cirrhosis and sAH, exhibit significant loss of hepatocytes. Various mechanisms and factors have been implicated in induction of hepatocyte death in ALD, such as alcohol metabolism&#8211;associated endoplasmic reticulum stress, oxidative stress, proinflammatory cytokines (e.g., TNF-&#945;), danger-associated molecular patterns, and dysregulation of autophagy, etc. (<xref rid="B18" ref-type="bibr">18</xref>). Several types of hepatocyte death have been reported and likely coexist in ALD, including apoptosis, necroptosis, pyroptosis, and ferroptosis (<xref rid="B18" ref-type="bibr">18</xref>). Hepatocyte death and impaired liver regeneration play an important role in promoting ALD progression and have been investigated as therapeutic targets. Selonsertib, a selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1), has been tested for the treatment of patients with sAH, owing to its inhibition of hepatocyte apoptosis, but no beneficial effects were found (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02854631">NCT02854631</ext-link>). Granulocyte colony-stimulating factor (G-CSF), which stimulates the bone marrow to produce granulocytes and hematopoietic stem cells, was thought to promote liver regeneration and was tested in clinical trials for sAH. However, the evidence for G-CSF stimulation of liver regeneration is insufficient (<xref rid="B19" ref-type="bibr">19</xref>), the clinical trial results for G-CSF were controversial in acute-on-chronic liver failure including AH, and G-CSF provided no survival benefit at 90 days in individuals with sAH, indicating that more evidence is required for further clinical investigation of G-CSF (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>). Finally, IL-22 may be an exceptional target that specifically protects against hepatocyte death and promotes hepatocyte proliferation without affecting immune cells owing to the restricted expression of IL-22 receptor on epithelial cells, including hepatocytes (<xref rid="B22" ref-type="bibr">22</xref>). The hepatoprotective effect of IL-22 has been demonstrated in a variety of liver injury models, including alcohol-induced liver injury (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). A phase IIb clinical trial revealed that treatment of patients with sAH with recombinant IL-22 protein was well tolerated and had improved clinical parameters (<xref rid="B25" ref-type="bibr">25</xref>). Ongoing multicenter trials are being conducted to investigate IL-22Fc treatment for acute-on-chronic liver failure, including sAH (CTR20212657).</p></sec><sec><title>Inflammation.</title><p>Inflammation acts as a key factor driving ALD progression to steatohepatitis, cirrhosis, and HCC (<xref rid="B17" ref-type="bibr">17</xref>); many different cell types and inflammatory mediators participate in the inflammation underlying ALD (<xref rid="F3" ref-type="fig">Figure 3</xref>). Paradoxically, alcohol is a well-known immunoregulator that strongly inhibits the immune system, causing the increased host susceptibility to bacterial and viral infections (<xref rid="B26" ref-type="bibr">26</xref>). The major factors that trigger ALD inflammation include hepatocyte death, increased gut permeability, and disrupted intestinal bacterial homeostasis (dysbiosis) (<xref rid="B17" ref-type="bibr">17</xref>). ALD inflammation is characterized by infiltration of neutrophils and macrophages, as well as activation of Kupffer cells and other types of immune cells (<xref rid="B17" ref-type="bibr">17</xref>), which play a dominant role in the pathogenesis of ALD. The detrimental effects of macrophages in ALD are likely due to production of a variety of inflammatory mediators (<xref rid="B17" ref-type="bibr">17</xref>), while neutrophils exacerbate ALD by producing ROS, inflammatory mediators, and neutrophil extracellular traps (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). On the other hand, macrophages and neutrophils play some beneficial roles in ameliorating ALD by promoting liver regeneration, fibrosis resolution, and antibacterial immunity, etc. (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). Significant infiltration of T cells is also observed in ALD, especially in the alcohol-associated cirrhosis, but their exact roles have not been well characterized in patients with ALD (<xref rid="B17" ref-type="bibr">17</xref>). Emerging evidence suggests that T cells have important profibrotic roles in metabolic dysfunction&#8211;associated steatotic liver disease (MASLD) (<xref rid="B29" ref-type="bibr">29</xref>), so it will be important to examine whether T cells also contribute to liver fibrogenesis in ALD. Interestingly, a negative correlation of intrahepatic neutrophils with intrahepatic CD8<sup>+</sup> T cells was observed in patients with sAH, and two distinct histopathological phenotypes were defined based on liver immune phenotyping, suggesting a separate mechanism driving liver injury and/or failure in these patients (<xref rid="B30" ref-type="bibr">30</xref>). A significant number of B cells are also seen in sAH, which is accompanied by massive antibody deposition and evidence for complement activation in hepatocytes, all of which play an important role in promoting liver injury in sAH (<xref rid="B31" ref-type="bibr">31</xref>). In addition, many other types of cells may also play a role in modulating ALD disease progression in preclinical models, including NKT cells, Th17 cells, and mucosal-associated invariant T cells, but their functions in ALD pathogenesis are not clear. Moreover, many proinflammatory mediators are upregulated and likely synergistically promote disease progression in ALD (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>).</p><p>Given its important role in the pathogenesis of ALD, inflammation has been actively investigated as a therapeutic target for sAH therapy. Steroids have been used to treat sAH since 1970s, and emerging data suggest that steroid treatment improves short-term survival in some patients with sAH without affecting long-term survival (<xref rid="B32" ref-type="bibr">32</xref>). Inhibition of specific inflammatory targets (e.g., TNF-&#945;, IL-1) has been investigated for sAH therapy, but this approach did not achieve good clinical benefit (<xref rid="B33" ref-type="bibr">33</xref>&#8211;<xref rid="B35" ref-type="bibr">35</xref>), which is likely because sAH is associated with elevation of many inflammatory mediators that have overlapping functions (<xref rid="F3" ref-type="fig">Figure 3</xref>) (<xref rid="B17" ref-type="bibr">17</xref>). The next question is whether we can directly target inflammatory cells to treat sAH. Significant numbers of infiltrating macrophages are detected in sAH, and these cells likely drive sAH inflammation and are potential targets for sAH therapy (<xref rid="B17" ref-type="bibr">17</xref>). Inhibition of macrophage infiltration by cenicriviroc, an oral dual chemokine receptor CCR2/CCR5 antagonist, generated some beneficial effects in preclinical models of MASLD (<xref rid="B36" ref-type="bibr">36</xref>) and ALD (<xref rid="B37" ref-type="bibr">37</xref>). However, recent studies have identified many subsets of macrophages, with some of them playing an important role in promoting liver repair and fibrosis resolution (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>), thus, selective inhibition of inflammatory macrophage infiltration may achieve better clinical outcomes for ALD treatment. Interestingly, binge alcohol intake or recent excessive drinking elevated circulating neutrophils and subsequently increased hepatic neutrophil infiltration and liver injury, which can be inhibited by blockade of C-X-C motif chemokine receptors 1 and 2 (CXCR1 and CXCR2) in preclinical models (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B40" ref-type="bibr">40</xref>&#8211;<xref rid="B43" ref-type="bibr">43</xref>). Targeting neutrophils for the treatment of sAH has not been explored clinically, but inhibition of CXCR1 and CXCR2 and other therapies that modulate neutrophils deserve further investigation. In addition, several other types of immune cells (e.g., T cells, NKT cells, mucosal-associated invariant T cells) have been implicated in the pathogenesis of AH (<xref rid="B17" ref-type="bibr">17</xref>); however, more clinical studies are required to clarify their functions in AH and evaluate their potential as therapeutic targets for AH therapy.</p></sec><sec><title>Gut dysfunction and dysbiosis.</title><p>Alcohol misuse can cause a profound impairment of intestinal functions, including a disease called alcohol-associated bowel disease (<xref rid="B44" ref-type="bibr">44</xref>). Alcohol-induced intestinal dysfunctions include malabsorption of nutrients, reduced villus-to-crypt ratio restricted to the duodenum, increased intestinal permeability, reduced production of antimicrobial molecules, increased mucus thickness, a striking diminution of mucosal immune cells, and gut microbiome-related changes (<xref rid="B44" ref-type="bibr">44</xref>). In general, reduction of immune cells in the intestine is a unique feature of alcohol-associated bowel disease, which is different from other intestinal diseases (e.g., celiac disease, inflammatory bowel disease) characterized by intestinal inflammation (<xref rid="B45" ref-type="bibr">45</xref>). Alcohol-mediated reduction of intestinal immune cells results in intestinal immune dysfunction and subsequently contributes to gut barrier disruption (<xref rid="B44" ref-type="bibr">44</xref>). However, how chronic alcohol consumption exactly affects different pro- and antiinflammatory immune cell populations in different intestinal tracts still remains unclear. Moreover, alcohol misuse and ALD are associated with small intestinal bacterial overgrowth, alterations of gut microbiota (&#8220;dysbiosis&#8221;), and bacterial translocation (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>). Gut dysbiosis was first reported in rats (<xref rid="B48" ref-type="bibr">48</xref>) and later in mice (<xref rid="B49" ref-type="bibr">49</xref>) after chronic ethanol exposure. In mice, chronic ethanol feeding increased the abundance of <italic toggle="yes">Bacteroidetes</italic> and <italic toggle="yes">Verrucomicrobia</italic> bacteria but decreased the abundance of lower <italic toggle="yes">Firmicutes</italic>, and these changes were associated with downregulation of antimicrobial <italic toggle="yes">Reg3g</italic> and <italic toggle="yes">Reg3b</italic> gene expression in the proximal small intestine (<xref rid="B49" ref-type="bibr">49</xref>). The Schnabl group later found that cytolysin secreted by <italic toggle="yes">Enterococcus faecalis</italic> causes hepatocyte death and liver injury (<xref rid="B50" ref-type="bibr">50</xref>). Increased fecal numbers of <italic toggle="yes">E</italic>. <italic toggle="yes">faecalis</italic> were found in patients with sAH, and the presence of cytolysin-positive (cytolytic) <italic toggle="yes">E</italic>. <italic toggle="yes">faecalis</italic> correlated with the severity and mortality of sAH (<xref rid="B50" ref-type="bibr">50</xref>). Colonization of gut microbiome from the feces of patients with sAH induced liver injury in mice, which can be ameliorated by bacteriophages that specifically target cytolytic <italic toggle="yes">E</italic>. <italic toggle="yes">faecalis</italic> (<xref rid="B50" ref-type="bibr">50</xref>). Emerging evidence suggests that ALD-associated changes in intestinal fungi also contribute to the pathogenesis of ALD by producing toxins and metabolites (<xref rid="B51" ref-type="bibr">51</xref>) and that the intestinal virome is altered in AH (<xref rid="B52" ref-type="bibr">52</xref>), but further study is required in these areas.</p><p>Restoring intestinal epithelial integrity and antimicrobial function and correcting dysbiosis are attractive strategies for ALD. Zinc is critical for maintenance of intestinal barrier function (<xref rid="B53" ref-type="bibr">53</xref>), and zinc deficiency is associated with ALD (<xref rid="B54" ref-type="bibr">54</xref>) and exacerbates ALD in preclinical models (<xref rid="B55" ref-type="bibr">55</xref>). Zinc supplementation has been included in the anti&#8211;IL-1 trial for sAH, but this trial did not improve sAH (<xref rid="B34" ref-type="bibr">34</xref>). In addition to protecting against liver injury, IL-22 also protects against gut epithelial injury, promotes gut epithelial cell regeneration, and restores intestinal immunity (<xref rid="B56" ref-type="bibr">56</xref>). Activation of IL-22 in the gut via bacteria engineered to produce IL-22 or produce aryl-hydrocarbon receptor agonists that upregulate IL-22 protects against ALD in mice (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>). Moreover, activation of intestinal epithelial aryl hydrocarbon receptor by microbial tryptophan metabolites improves alcohol-mediated gut barrier dysfunction and has potential as a therapeutic target for ALD (<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B60" ref-type="bibr">60</xref>). Targeting microbiome and mycobiome toxins have been actively investigated for the treatment of ALD (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>). Fecal microbiota transplantation as well as antibiotics, probiotics, and prebiotics have been tested or proposed as gut microbiome-centered therapies for ALD, but the results are inconsistent (<xref rid="B61" ref-type="bibr">61</xref>&#8211;<xref rid="B64" ref-type="bibr">64</xref>). Given the high heterogeneity of the gut microbiome in humans, the descriptive nature of the microbiome studies so far, and the lack of a definition for a &#8220;healthy&#8221; microbiome (<xref rid="B65" ref-type="bibr">65</xref>), it is difficult to have conclusive results. It is unlikely that targeting the gut microbiome alone will be sufficient to treat ALD in all patients.</p></sec><sec><title>Ductular reaction.</title><p>Ductular reaction (DR) is associated with advanced ALD and is characterized by an increased number of cholangiocytes along with inflammatory cell infiltration and loss of hepatocytes (<xref rid="B66" ref-type="bibr">66</xref>). The origin of the expanded cholangiocytes is controversial, and multiple origins have been proposed, including cholangiocyte proliferation, hepatic progenitor cell differentiation into cholangiocytes, and dedifferentiation of hepatocytes toward a cholangiocyte-like phenotype (<xref rid="B66" ref-type="bibr">66</xref>). Thus, targeting DR to preferentially differentiate hepatic progenitor cells into hepatocytes is a potential strategy for the treatment of advanced ALD. Several drivers of DR have been identified, including modulation of biliary NF-&#954;B activity, long noncoding RNA <italic toggle="yes">ACTA2-AS1</italic>, mTOR activation, CXCR4-mediated hepatocyte dedifferentiation, and neutrophil or macrophage infiltration (<xref rid="B67" ref-type="bibr">67</xref>&#8211;<xref rid="B76" ref-type="bibr">76</xref>). Of these, inflammation-mediated DR, mTOR activation, and biliary NF-&#954;B activity alterations seem to be present in human ALD samples, indicating their translational significance. However, targeting the mTOR and NF-&#954;B pathways specifically in cholangiocytes is difficult and, therefore, inhibiting inflammatory exacerbation of DR may hold the most potential as a therapeutic approach. Regardless, DR is associated with worse prognosis in ALD, and therapeutics that reverse DR, hepatocyte dedifferentiation, and the cholestatic phenotype hold potential for ALD treatment.</p></sec><sec><title>Hepatic mitochondrial dysfunction.</title><p>Hepatocytes are rich in mitochondria, which play important roles in glucose, lipid, and protein metabolism as well as ROS homeostasis. A wide range of studies have found that heavy alcohol consumption causes impairment of mitochondrial biogenesis, mitochondrial DNA damage, and subsequent oxidative stress and cell death (<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>). In addition, formation of megamitochondria in hepatocytes has been a known effect of heavy alcohol use since the 1970s (<xref rid="B79" ref-type="bibr">79</xref>), but how these changes are related to ALD progression were unknown until recently. The Ding lab demonstrated that alcohol consumption decreased hepatic dynamin-related protein 1 (DRP1), a protein involved in mitochondrial fission, and induced megamitochondria in cells and a mouse model of ALD (<xref rid="B80" ref-type="bibr">80</xref>). Patients with sAH have decreased hepatic DRP1 that is associated with increased accumulation of megamitochondria in the liver, and genetic deletion of the <italic toggle="yes">Drp1</italic> gene markedly exacerbates ALD in mice, supporting the role of mitochondrial dysfunction in ALD progression (<xref rid="B80" ref-type="bibr">80</xref>). Additionally, another study suggests that activation of hepatic activating transcription factor 4 acts as a driver of alcohol-impaired mitochondrial biogenesis and respiratory function (<xref rid="B81" ref-type="bibr">81</xref>). Defective mitochondrial respiratory function can provoke elevated ROS production and subsequently sensitize hepatocytes to death, a key event in ALD progression (<xref rid="B79" ref-type="bibr">79</xref>). Collectively, these recent studies suggest that modulating mitochondrial homeostasis in ALD is a potential therapeutic strategy and requires further characterization.</p></sec><sec><title>Other potential mechanisms and therapeutic targets.</title><p>Over the last 20 years, many molecular mechanisms have been identified that may contribute to the pathogenesis of ALD (<xref rid="B18" ref-type="bibr">18</xref>), but translation of these mechanisms to therapeutic targets needs further attention. For example, alcohol consumption causes adipose inflammation, lipolysis, and damage, which likely contribute to ALD pathogenesis (<xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B83" ref-type="bibr">83</xref>). Moreover, dysregulation of lipid metabolism contributes to MASLD progression by inducing hepatocyte death and has been actively investigated as a therapeutic target for MASLD (<xref rid="B84" ref-type="bibr">84</xref>), but its role in sAH and whether it can be used as a therapeutic target for ALD is unclear. An endogenous cholesterol derivative, 25-hydroxycholesterol 3-sulfate (larsucosterol), was found to inhibit liver lipid accumulation and improve cell survival by inhibiting DNA methyltransferases, which has shown promise in a phase IIa clinical study for moderate and sAH (<xref rid="B85" ref-type="bibr">85</xref>). Several therapies targeting ROS have shown mixed effects for sAH treatment, with N-acetyl cystine (NAC) providing no benefit (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B87" ref-type="bibr">87</xref>) and metadoxine providing modest survival benefits (<xref rid="B88" ref-type="bibr">88</xref>). Autophagy has been shown to play an important but complex role in the pathogenesis of liver diseases, including ALD (<xref rid="B89" ref-type="bibr">89</xref>, <xref rid="B90" ref-type="bibr">90</xref>), but has not been tested clinically as a therapeutic target for ALD due to its highly complex, cell-specific roles (<xref rid="B91" ref-type="bibr">91</xref>). Many miRNAs have been found to modulate ALD disease progression, but the application of these miRNAs as therapeutic targets in ALD treatment is still at the early stage of investigation (<xref rid="B92" ref-type="bibr">92</xref>). Further translational studies are required to test the therapeutic potential of autophagy modulators and miRNAs for ALD treatment.</p></sec></sec><sec><title>Application of cutting-edge technologies in ALD</title><sec><title>Multiomics analysis of ALD.</title><p>The emergence and application of -omics (genomics, transcriptomics, proteomics, metabolomics) technologies to ALD in preclinical and clinical models over the past 20 years have provided a wealth of data about the genetic polymorphisms and signaling pathways that drive the progression of ALD (<xref rid="T2" ref-type="table">Table 2</xref> and <xref rid="T3" ref-type="table">Table 3</xref>). Human GWAS identified risk factors for ALD, including polymorphisms in <italic toggle="yes">PNPLA3</italic>, <italic toggle="yes">MBOAT7</italic>, <italic toggle="yes">TM6SF2</italic>, <italic toggle="yes">MARC1</italic>, <italic toggle="yes">HNRNPUL1</italic>, <italic toggle="yes">HSD17B13</italic>, and other genes (<xref rid="T4" ref-type="table">Table 4</xref>), many of which are also risk factors for other types of liver diseases (further detailed in <italic toggle="yes">Heterogeneity of ALD</italic> below) (<xref rid="B93" ref-type="bibr">93</xref>&#8211;<xref rid="B99" ref-type="bibr">99</xref>).</p><p>One of the first microarray studies in ethanol-fed mice identified numerous pathways altered by ethanol, including fatty acid metabolism, glutathione metabolism, and cytokine signaling, providing several previously unknown ethanol-regulated genes for further study (<xref rid="B100" ref-type="bibr">100</xref>). In addition, the application of transcriptomics to human ALD samples has provided much more information about the pathogenesis of ALD, mostly due to the inability of the current preclinical ethanol-feeding models to recapitulate all hallmarks of human ALD. Early transcriptomic studies of human AH identified dysregulation of the TNF receptor superfamily member 12 A (TNRSF12A), and integration of this data set with microarray analysis of the chronic-plus-binge mouse model identified fat-specific protein 27/cell death inducing DFFA-like effector C (FSP27/CIDEC) as a driver gene of ASH in mice and humans (<xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B102" ref-type="bibr">102</xref>). Several other mouse transcriptomic studies have enhanced our understanding of ALD, including the role of gasdermin D&#8211;mediated pyroptosis and neutrophil cytosolic factor 1&#8211;mediated oxidative stress, among others (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B103" ref-type="bibr">103</xref>&#8211;<xref rid="B107" ref-type="bibr">107</xref>). Expanding access to RNA-Seq technologies has led to more transcriptomic studies in mouse and human ALD, especially over the past 5 years. One of the key studies by Argemi et al. integrated GWAS and methylomic data with RNA-Seq data to identify hepatocyte nuclear factor 4&#945; (HNF4&#945;) dysregulation and subsequent hepatocyte dedifferentiation as a major contributor to ALD progression (<xref rid="B108" ref-type="bibr">108</xref>).</p><p>Integration of transcriptomics with other -omics technologies, including proteomics and metabolomics, has led to big leaps in our understanding of ALD and the identification of potential biomarkers. By applying proteome microarrays, one recent study found that livers from patients with sAH contain a large number of autoantibodies that are not present in circulation, and deposition of these antibodies likely participates in sAH inflammation (<xref rid="B31" ref-type="bibr">31</xref>). Studies combining transcriptomics with proteomics have identified and validated potential plasma biomarkers of ALD (<xref rid="B109" ref-type="bibr">109</xref>, <xref rid="B110" ref-type="bibr">110</xref>). Several other studies investigating circulating biomarkers for ALD have identified lncRNAs, small RNAs, metabolites, proteins, and the circulating transcriptome as potential identifiers of ALD (<xref rid="B111" ref-type="bibr">111</xref>&#8211;<xref rid="B118" ref-type="bibr">118</xref>). Further validation of these potential biomarkers and integration with ALD severity scoring will be essential for proper diagnoses and potentially could be expanded to determine whether patients will respond to a specific therapy once more ALD therapeutics become available. One study used liver biopsy transcriptomes to determine whether patients would respond to corticosteroid therapy, and application of circulating biomarkers to the potential for response to treatment will begin to lead to personalized medicine in the future (<xref rid="B119" ref-type="bibr">119</xref>).</p><p>The advances from simple RNA-Seq toward single-cell and spatial transcriptomics will likely drive the next wave of discoveries surrounding ALD. Indeed, by utilizing scRNA-Seq analysis, two studies have identified new cell subpopulations that drive fibrosis and inflammation in the mouse AH model and human alcohol-associated cirrhosis (<xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B121" ref-type="bibr">121</xref>). In addition, a previous study using microdissection to determine gene expression in different spatial areas found that increased yes-associated protein (YAP) signaling in hepatocytes leads to biliary transdifferentiation as a mechanism of AH (<xref rid="B122" ref-type="bibr">122</xref>). Epigenetics in ALD has also been received much attention in the past (<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B124" ref-type="bibr">124</xref>), while gene splicing is another area that has been investigated recently. For example, Hyun et al. recently found that epithelial splicing regulatory protein 2 plays an important role in controlling hepatocyte reprogramming in AH (<xref rid="B125" ref-type="bibr">125</xref>). Another study reported that serine-arginine-rich protein kinase 2, a key kinase controlling alternative splicing, is activated in hepatocytes in response to alcohol and promotes ALD in mice (<xref rid="B126" ref-type="bibr">126</xref>).</p></sec><sec><title>Multiplex immunofluorescence staining analysis of ALD.</title><p>Advances in protocols for staining and visualization of formalin-fixed paraffin-embedded (FPPE) tissues have enabled labs with little to no specialized equipment to conduct multiplex immunofluorescence staining. This allows users to investigate the spatial distribution of cell types and proteins of interest through staining and visualizing more than 12 different proteins (<xref rid="B127" ref-type="bibr">127</xref>). This technique has been widely applied to investigate the tumor microenvironment and other types of liver disease but has only recently been utilized to interrogate the pathology of ALD (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B71" ref-type="bibr">71</xref>). By using multiplex immunofluorescence staining, we detected high numbers of macrophages near DR in sAH, suggesting that macrophages play a role in promoting DR (<xref rid="B127" ref-type="bibr">127</xref>). Indeed, a study from an experimental model revealed that macrophages promote ductular cell repair and proliferation after acute bile duct injury (<xref rid="B128" ref-type="bibr">128</xref>).</p></sec></sec><sec><title>Preclinical models of ALD</title><p>Chronic alcohol feeding via either voluntary intake or intragastric tube has been used to induce ALD in animals over the last 4 decades (<xref rid="B129" ref-type="bibr">129</xref>&#8211;<xref rid="B132" ref-type="bibr">132</xref>) (<xref rid="T5" ref-type="table">Table 5</xref>). Such chronic feeding induces steatosis and liver injury with activation of macrophages but lacks neutrophil infiltration (a hallmark of AH). In 2010, we introduced binge ethanol intake into the chronically ethanol-fed mice, which causes significant neutrophil infiltration and liver injury (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B133" ref-type="bibr">133</xref>). Thereafter, this chronic-plus-binge model has been widely used in the field and is considered as a model for mild AH over the last decade (<xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B135" ref-type="bibr">135</xref>). In addition, many &#8220;second-hit&#8221; models of liver injury in combination of ethanol with other insults have also been developed (<xref rid="B136" ref-type="bibr">136</xref>). By using these models together with analysis of human ALD samples, many novel molecular pathways and mechanisms involved in pathogenesis of ALD have been identified (<xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B135" ref-type="bibr">135</xref>). Recently, the combination of alcohol and Western diets has been actively tested in mouse models. Single or multiple binges of ethanol exacerbate liver injury in mice fed a high-fat diet (HFD) (<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B137" ref-type="bibr">137</xref>, <xref rid="B138" ref-type="bibr">138</xref>) or Western diet (<xref rid="B139" ref-type="bibr">139</xref>). Chronic alcohol feeding via intragastric tube has also been applied in mice fed a Western diet (<xref rid="B140" ref-type="bibr">140</xref>), but voluntary ethanol feeding in combination with HFD is challenging due to decreased food intake in ethanol groups compared with the pair-fed control groups (our unpublished data). Interestingly recent studies reported that ethanol in drinking water and/or binge ethanol intake exacerbated liver injury in mice fed the Western diet (<xref rid="B141" ref-type="bibr">141</xref>, <xref rid="B142" ref-type="bibr">142</xref>), which is required further characterization.</p></sec><sec><title>Interplay of ALD and metabolic dysfunction</title><p>There have been recent changes in the nomenclature for liver disease, with steatotic liver disease, which encompasses all types of fatty liver diseases, now termed MASLD, which replaces the stigmatizing &#8220;nonalcoholic fatty liver disease&#8221; (NAFLD), and a new category, called MetALD, which includes patients with MASLD who also have significant alcohol consumption (<xref rid="B143" ref-type="bibr">143</xref>, <xref rid="B144" ref-type="bibr">144</xref>). The combination of metabolic dysfunction and heavy alcohol consumption in this unique patient population exhibits overlapping and distinct mechanisms of liver disease progression which have been recently reviewed (<xref rid="B145" ref-type="bibr">145</xref>). As the rates of metabolic dysfunction are increasing in populations across the world, MetALD should be a priority for study going forward.</p></sec><sec><title>Alcohol-associated cirrhosis</title><p>Alcohol-associated cirrhosis causes an estimated 25% of global deaths due to liver cirrhosis and up to 40% in certain areas of Europe (<xref rid="B146" ref-type="bibr">146</xref>). In addition, deaths due to alcohol-associated cirrhosis in the United States have risen in younger individuals and are projected to rise precipitously up to 2040 (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B147" ref-type="bibr">147</xref>). While alcohol-associated cirrhosis represents a distinct etiology of cirrhosis, its diagnosis and treatment are relatively similar to MASLD- and viral-initiated cirrhosis, which have been recently reviewed (<xref rid="B148" ref-type="bibr">148</xref>). It is essential to treat the underlying AUD in patients with alcohol-associated cirrhosis to improve outcomes (<xref rid="B14" ref-type="bibr">14</xref>).</p></sec><sec><title>Alcohol-associated liver cancer</title><p>Recent epidemiological data revealed that alcohol contributes to an estimated 19% of liver cancer deaths globally, and the age-standardized death rate of alcohol-associated liver cancer increased by 0.53% annually in the past few years (<xref rid="B149" ref-type="bibr">149</xref>, <xref rid="B150" ref-type="bibr">150</xref>). Although alcohol drinking is a well-known risk factor for liver cancer, especially HCC, A-HCC is poorly characterized compared with HCC caused by other etiologies (<xref rid="B151" ref-type="bibr">151</xref>). Among patients with ALD, the annual incidence of A-HCC is 5.6 cases per 1,000 person-years (<xref rid="B152" ref-type="bibr">152</xref>). Moreover, patients with A-HCC tend to be diagnosed with advanced stage disease compared with patients with other etiologies of HCC (<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B154" ref-type="bibr">154</xref>), which is partially due to a lack of access to early screening in populations with ALD (<xref rid="B155" ref-type="bibr">155</xref>). Of note, compared with the general population, the relative risk (RR) of HCC was 2.4 for AUD alone, and the presence of cirrhosis increased the RR of developing HCC among people with AUD to 22.4 (<xref rid="B156" ref-type="bibr">156</xref>). Cirrhosis is a necessary intermediate step for A-HCC development and amplifies the overall risk for carcinogenesis in patients with ALD (<xref rid="B157" ref-type="bibr">157</xref>, <xref rid="B158" ref-type="bibr">158</xref>). Analysis of causes of death for Danish patients with ALD revealed that the majority of deaths are due to the liver disease itself in the 5 years after diagnosis, after which extrahepatic cardiovascular, cancer, AUD-related deaths become more common, while individual cancers, including A-HCC, are minor contributors to ALD-related mortality (<xref rid="B159" ref-type="bibr">159</xref>). However, improved ALD treatments in the future will likely increase longevity of patients with ALD, which may lead to an increase in a number of patients with A-HCC.</p><p>Currently, there are no ideal animal models for A-HCC study. Despite most available A-HCC mouse models combining the carcinogenic agent N-nitrosodiethylamine with long-term ethanol feeding (<xref rid="B160" ref-type="bibr">160</xref>), their clinical relevance to human A-HCC is still questionable. Developing appropriate preclinical models of A-HCC might improve translation of basic science into clinical practice, which may provide a better understanding of hepatocarcinogenesis in patients with ALD.</p></sec><sec><title>Heterogeneity of ALD</title><p>ALD is a heterozygous disease characterized by a spectrum of disorders, and this heterogeneity likely contributes to the failing of various clinical trials for ALD treatment (<xref rid="B4" ref-type="bibr">4</xref>). A better understanding of how factors such as genetics, drinking pattern, dietary effects, bacterial infection, and comorbidities alter mechanisms behind the development and pathogenesis of ALD is essential and may lead to personalized treatments for ALD (<xref rid="B4" ref-type="bibr">4</xref>).</p><sec><title>Genetic heterogeneity in ALD.</title><p>As described above, GWAS have been utilized to link genetic associations with risks of developing ALD and subsequent outcomes (<xref rid="T3" ref-type="table">Tables 3</xref> and <xref rid="T4" ref-type="table">4</xref>) (the full gene names are listed in the <xref rid="T4" ref-type="table">Table 4</xref>). The two most robustly replicated single nucleotide polymorphisms, rs738409(C&gt;G) in <italic toggle="yes">PNPLA3</italic> and rs58542926(C&gt;T) in <italic toggle="yes">TM6SF2</italic>, are closely related to the increased risk for developing the entire spectrum of ALD (<xref rid="B161" ref-type="bibr">161</xref>). As lipid turnover&#8211;related genes, <italic toggle="yes">PNPLA3</italic> rs738409 variant and <italic toggle="yes">TM6SF2</italic> rs58542926 variant are involved in abnormal hydrolysis of triglycerides and very-low-density lipoprotein secretion (<xref rid="B162" ref-type="bibr">162</xref>), which are significantly associated with a higher risk for alcohol-associated cirrhosis and may predispose patients with cirrhosis to A-HCC (<xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B163" ref-type="bibr">163</xref>). <italic toggle="yes">MBOAT7</italic> rs641738 and <italic toggle="yes">NCAN</italic> rs2228603, two common variants related to the development and severity of MASLD as well as liver fat content (<xref rid="B164" ref-type="bibr">164</xref>, <xref rid="B165" ref-type="bibr">165</xref>), are found to increase the risk for cirrhosis and HCC development in ALD (<xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B166" ref-type="bibr">166</xref>). Many of the genes associated with increased risks of ALD progression (<xref rid="T4" ref-type="table">Table 4</xref>) are linked to increases in liver fat content, but exactly how these changes lead to carcinogenesis in the setting of cirrhosis requires further study. Additionally, <italic toggle="yes">WNT3A-WNT9A</italic> rs708113 was recently identified as a susceptibility locus for A-HCC; however, more evidence is needed to clarify its gene-alcohol interactions (<xref rid="B161" ref-type="bibr">161</xref>). Moreover, polymorphisms of ethanol metabolic genes (e.g., <italic toggle="yes">ADH1C*1</italic> and <italic toggle="yes">ALDH2*2</italic>) may also influence an individual&#8217;s susceptibility to A-HCC (<xref rid="B167" ref-type="bibr">167</xref>&#8211;<xref rid="B169" ref-type="bibr">169</xref>). Conversely, some newly identified genetic polymorphisms may play protective roles in ALD progression. The rs2242652 germline variant in <italic toggle="yes">TERT</italic> and variants of several lipid metabolism&#8211;related genes, including <italic toggle="yes">MARC1</italic> rs2642438, <italic toggle="yes">APOE</italic> rs429358, <italic toggle="yes">HSD17B13</italic> rs72613567, and <italic toggle="yes">LPL</italic> rs13702, are associated with reduced risk for cirrhosis or HCC development in patients with ALD (<xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B170" ref-type="bibr">170</xref>&#8211;<xref rid="B172" ref-type="bibr">172</xref>). There are a few things to keep in mind with these studies. The first is that some of these genetic association studies have been conducted in relatively small populations, and replication of these findings in larger cohorts will be important. In addition, the levels of evidence for the association of each of these polymorphisms with ALD vary across the different disease stages. Finally, many of the genetic risk factors for ALD are different from those for AUD, with the finding that only a subset of patients with AUD ever progress past steatosis to more severe stages of ALD (<xref rid="B173" ref-type="bibr">173</xref>).</p></sec><sec><title>Comparing alcohol metabolism and ALD in Eastern and Western populations.</title><p>More than 90% of ingested alcohol is metabolized into acetaldehyde by oxidative enzymes alcohol dehydrogenase (ADH) and to much lesser extent by cytochrome P450 2E1 and catalase. Acetaldehyde is converted further into acetate by mitochondrial aldehyde dehydrogenase 2 (ALDH2). The traditional notion of the liver as a major site for ethanol metabolism is challenged by our recent study showing that deletion of the liver <italic toggle="yes">Aldh2</italic> gene reduced blood acetaldehyde clearance only by approximately 30% compared with that in global <italic toggle="yes">Aldh2</italic>-knockout mice (<xref rid="B7" ref-type="bibr">7</xref>), suggesting many other organs that express ALDH2 also contribute to acetaldehyde metabolism. Additionally, alcohol can also be metabolized by a nonoxidative pathway to generate lipophilic fatty acid ethyl esters (FAEEs), which also promotes liver injury (<xref rid="B174" ref-type="bibr">174</xref>); however, more studies are required to clarify the role of FAEEs in ALD pathogenesis.</p><p>People from Asia and Western countries have significant differences in ethanol metabolism due to the polymorphisms in <italic toggle="yes">ADH</italic> and <italic toggle="yes">ALDH2</italic>. For example, 30%&#8211;40% of individuals from eastern Asia have inactive <italic toggle="yes">ALDH2</italic> polymorphisms (<italic toggle="yes">ALDH2*2/1, ALDH2*2/2</italic>) (<xref rid="B175" ref-type="bibr">175</xref>), and approximately 70% of these individuals have <italic toggle="yes">ADH</italic> polymorphisms with higher ADH activity (<xref rid="B176" ref-type="bibr">176</xref>). Thus, many Asians drink less alcohol but generate much higher levels of acetaldehyde, exhibit flushing, and generate lower levels of ethanol-derived acetate compared with the people from Western countries, which may differently affect ALD development and progression (<xref rid="B177" ref-type="bibr">177</xref>). Mounting evidence suggests that ethanol consumption among those harboring the <italic toggle="yes">ALDH2*2</italic> polymorphism is rising, and identifying any differences in ALD pathogenesis in this population will become increasingly important (<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B179" ref-type="bibr">179</xref>). Preclinical models revealed that mice with ALDH2 deficiency have more inflammation and fibrosis and greater immunosuppression but lower levels of steatosis and serum ALT compared with control mice after ethanol intake (<xref rid="B174" ref-type="bibr">174</xref>, <xref rid="B180" ref-type="bibr">180</xref>, <xref rid="B181" ref-type="bibr">181</xref>). Therefore, the pathogenesis of ALD between the East and the West may exhibit some differences, and we may need different diagnosis guidelines and therapy for those with inactive ALDH2 and/or greater ADH activity in Asia.</p></sec><sec><title>Sex disparities in ALD.</title><p>There is a clear sex disparity regarding the epidemiology of ALD. Women are more susceptible to ALD than men with the same amount of alcohol intake, although the exact mechanisms are still unclear (<xref rid="B151" ref-type="bibr">151</xref>). The RR of developing ALD is 3.7 in men and 7.3 in women (<xref rid="B182" ref-type="bibr">182</xref>). The risk of alcohol-related cirrhosis in male and female heavy drinkers (at age 40 years, with 10 drinks/day for more than 15 years) is 3.1% and 4.7%, respectively (<xref rid="B183" ref-type="bibr">183</xref>, <xref rid="B184" ref-type="bibr">184</xref>). Additionally, compared with men, women with AH are generally younger but have higher rates of AH-related complications, comorbidities, and mortality (<xref rid="B185" ref-type="bibr">185</xref>). Moreover, even though more men overall have ALD, the increase in ALD mortality is more rapid among women than men (<xref rid="B186" ref-type="bibr">186</xref>&#8211;<xref rid="B188" ref-type="bibr">188</xref>). Therefore, identifying gender-related mechanisms underlying the higher risks of ALD in women should be a priority for further study.</p></sec></sec><sec><title>Conclusions and translational research prospects</title><p>Despite of extensive research on ALD over the last four decades, there are still no FDA-approved drugs for ALD. We have detailed some potential translational research prospects for ALD in <xref rid="T6" ref-type="table">Table 6</xref>, but we believe that new cutting-edge technologies applied to samples from patients with ALD and experimental models in many other areas will also yield valuable information for ALD pathogenesis and treatment. Hepatocyte death, impaired liver regeneration, inflammation, DR, and organ-liver crosstalk all play key roles in promoting ALD and represent areas for therapeutic development. A better understanding of the gut-liver axis during ALD progression is needed, and future studies should rigorously investigate intestinal immunity&#8211;microbiome interactions in the context of alcohol use. In addition, all current mouse models of ALD generate mild-to-moderate liver injury, inflammation, and fibrosis or fibrotic responses. Even combination treatment of alcohol with other insults did not recapitulate the full spectrum of human ALD in mice. Many factors may contribute to the resistance of severe ALD in mice, including but not limited to much faster ethanol metabolism, low neutrophil count, and lack of the key neutrophil chemokine CXCL8 (IL-8) and CXCL6 in mice (<xref rid="B189" ref-type="bibr">189</xref>). Mice with genetic modification of these factors should be tested for ALD. In addition, combination of alcohol with different diets in preclinical models should be tested, which may identify dietary factors that play an important role in ALD. In addition, the recent advances in rapid in vivo multiplexed editing of the adult mouse liver using CRISPR/caspase-9 will likely help to identify how different systems interact in ALD in preclinical models (<xref rid="B190" ref-type="bibr">190</xref>). Finally, development of ALD biomarkers is also essential for the early diagnosis of clinically &#8220;silent&#8221; ALD, allowing early intervention with AUD therapy to decrease alcohol consumption and potentially reverse ALD in some patients.</p></sec><sec><title>Author contributions</title><p>BM and YF wrote the manuscript and contributed equally. LM wrote the gut dysfunction and dysbiosis parts of the manuscript and edited it. BG wrote and edited the manuscript and supervised the whole project.</p></sec></body><back><ack><p>The authors thank members of the Laboratory of Liver Diseases for their dedication to new discoveries and ideas in the field of ALD. The authors also apologize for many ALD-related papers that were not able to be cited and discussed owing to space and scope limitations. The work from the Bin Gao&#8217;s laboratory described in this Review was supported by the intramural program of National Institute on Alcohol Abuse and Alcoholism, NIH (to BG).</p></ack><fn-group><fn><p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p></fn><fn><p><bold>Copyright:</bold> &#169; 2024, Mackowiak et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.</p></fn><fn><p><bold>Reference information:</bold><italic toggle="yes"> J Clin Invest</italic>. 2024;134(3):e176345. https://doi.org/10.1172/JCI176345.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Julien</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study</article-title><source>Lancet Public Health</source><year>2020</year><volume>5</volume><issue>6</issue><fpage>e316</fpage><lpage>e323</lpage><pub-id pub-id-type="doi">10.1016/S2468-2667(20)30062-1</pub-id><pub-id pub-id-type="pmid">32504584</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asrani</surname><given-names>SK</given-names></name><etal>et al</etal></person-group><article-title>Reducing the global burden of alcohol-associated liver disease: a blueprint for action</article-title><source>Hepatology</source><year>2021</year><volume>73</volume><issue>5</issue><fpage>2039</fpage><lpage>2050</lpage><pub-id pub-id-type="doi">10.1002/hep.31583</pub-id><pub-id pub-id-type="pmid">32986883</pub-id><pub-id pub-id-type="pmcid">PMC9361217</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devarbhavi</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Global burden of liver disease: 2023 update</article-title><source>J Hepatol</source><year>2023</year><volume>79</volume><issue>2</issue><fpage>516</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.03.017</pub-id><pub-id pub-id-type="pmid">36990226</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>B</given-names></name><name name-style="western"><surname>Bataller</surname><given-names>R</given-names></name></person-group><article-title>Alcoholic liver disease: pathogenesis and new therapeutic targets</article-title><source>Gastroenterology</source><year>2011</year><volume>141</volume><issue>5</issue><fpage>1572</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.09.002</pub-id><pub-id pub-id-type="pmid">21920463</pub-id><pub-id pub-id-type="pmcid">PMC3214974</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crabb</surname><given-names>DW</given-names></name><etal>et al</etal></person-group><article-title>Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia</article-title><source>Gastroenterology</source><year>2016</year><volume>150</volume><issue>4</issue><fpage>785</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.02.042</pub-id><pub-id pub-id-type="pmid">26921783</pub-id><pub-id pub-id-type="pmcid">PMC5287362</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bataller</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Alcohol-associated hepatitis</article-title><source>N Engl J Med</source><year>2022</year><volume>387</volume><issue>26</issue><fpage>2436</fpage><lpage>2448</lpage><pub-id pub-id-type="doi">10.1056/NEJMra2207599</pub-id><pub-id pub-id-type="pmid">36577100</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guillot</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Targeting liver aldehyde dehydrogenase-2 prevents heavy but not moderate alcohol drinking</article-title><source>Proc Natl Acad Sci U S A</source><year>2019</year><volume>116</volume><issue>51</issue><fpage>25974</fpage><lpage>25981</lpage><pub-id pub-id-type="doi">10.1073/pnas.1908137116</pub-id><pub-id pub-id-type="pmid">31792171</pub-id><pub-id pub-id-type="pmcid">PMC6926021</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramchandani</surname><given-names>VA</given-names></name><etal>et al</etal></person-group><article-title>Research advances in ethanol metabolism</article-title><source>Pathol Biol (Paris)</source><year>2001</year><volume>49</volume><issue>9</issue><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1016/S0369-8114(01)00232-2</pub-id><pub-id pub-id-type="pmid">11762128</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemente-Sanchez</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Moderate alcoholic hepatitis</article-title><source>Clin Liver Dis</source><year>2021</year><volume>25</volume><issue>3</issue><fpage>537</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2021.03.001</pub-id><pub-id pub-id-type="pmid">34229838</pub-id><pub-id pub-id-type="pmcid">PMC8757441</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vatsalya</surname><given-names>V</given-names></name><etal>et al</etal></person-group><article-title>The beneficial effects of lactobacillus GG therapy on liver and drinking assessments in patients with moderate alcohol-associated hepatitis</article-title><source>Am J Gastroenterol</source><year>2023</year><volume>118</volume><issue>8</issue><fpage>1457</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.14309/ajg.0000000000002283</pub-id><pub-id pub-id-type="pmid">37040544</pub-id><pub-id pub-id-type="pmcid">PMC10524173</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louvet</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study</article-title><source>Lancet Gastroenterol Hepatol</source><year>2022</year><volume>7</volume><issue>5</issue><fpage>416</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(21)00430-1</pub-id><pub-id pub-id-type="pmid">35202597</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crabb</surname><given-names>DW</given-names></name><etal>et al</etal></person-group><article-title>Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases</article-title><source>Hepatology</source><year>2020</year><volume>71</volume><issue>1</issue><fpage>306</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1002/hep.30866</pub-id><pub-id pub-id-type="pmid">31314133</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogal</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis</article-title><source>Hepatology</source><year>2020</year><volume>71</volume><issue>6</issue><fpage>2080</fpage><lpage>2092</lpage><pub-id pub-id-type="doi">10.1002/hep.31042</pub-id><pub-id pub-id-type="pmid">31758811</pub-id><pub-id pub-id-type="pmcid">PMC8032461</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vannier</surname><given-names>AGL</given-names></name><etal>et al</etal></person-group><article-title>Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder</article-title><source>JAMA Netw Open</source><year>2022</year><volume>5</volume><issue>5</issue><elocation-id>e2213014</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.13014</pub-id><pub-id pub-id-type="pmid">35594048</pub-id><pub-id pub-id-type="pmcid">PMC9123494</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seitz</surname><given-names>HK</given-names></name><etal>et al</etal></person-group><article-title>Alcoholic liver disease</article-title><source>Nat Rev Dis Primers</source><year>2018</year><volume>4</volume><issue>1</issue><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1038/s41572-018-0014-7</pub-id><pub-id pub-id-type="pmid">30115921</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avila</surname><given-names>MA</given-names></name><etal>et al</etal></person-group><article-title>Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting</article-title><source>Gut</source><year>2020</year><volume>69</volume><issue>4</issue><fpage>764</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2019-319720</pub-id><pub-id pub-id-type="pmid">31879281</pub-id><pub-id pub-id-type="pmcid">PMC7236084</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Inflammatory pathways in alcoholic steatohepatitis</article-title><source>J Hepatol</source><year>2019</year><volume>70</volume><issue>2</issue><fpage>249</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.10.023</pub-id><pub-id pub-id-type="pmid">30658726</pub-id><pub-id pub-id-type="pmcid">PMC6361545</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Recent advances in understanding of pathogenesis of alcohol-associated liver disease</article-title><source>Annu Rev Pathol</source><year>2023</year><volume>18</volume><fpage>411</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-031521-030435</pub-id><pub-id pub-id-type="pmid">36270295</pub-id><pub-id pub-id-type="pmcid">PMC10060166</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spahr</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial</article-title><source>Hepatology</source><year>2008</year><volume>48</volume><issue>1</issue><fpage>221</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1002/hep.22317</pub-id><pub-id pub-id-type="pmid">18537187</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engelmann</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)</article-title><source>J Hepatol</source><year>2021</year><volume>75</volume><issue>6</issue><fpage>1346</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.07.033</pub-id><pub-id pub-id-type="pmid">34364917</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tayek</surname><given-names>JA</given-names></name><etal>et al</etal></person-group><article-title>A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis</article-title><source>EClinicalMedicine</source><year>2022</year><volume>54</volume><elocation-id>101689</elocation-id><pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101689</pub-id><pub-id pub-id-type="pmid">36267499</pub-id><pub-id pub-id-type="pmcid">PMC9576807</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radaeva</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation</article-title><source>Hepatology</source><year>2004</year><volume>39</volume><issue>5</issue><fpage>1332</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1002/hep.20184</pub-id><pub-id pub-id-type="pmid">15122762</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ki</surname><given-names>SH</given-names></name><etal>et al</etal></person-group><article-title>Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3</article-title><source>Hepatology</source><year>2010</year><volume>52</volume><issue>4</issue><fpage>1291</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1002/hep.23837</pub-id><pub-id pub-id-type="pmid">20842630</pub-id><pub-id pub-id-type="pmcid">PMC2947578</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice</article-title><source>J Hepatol</source><year>2020</year><volume>72</volume><issue>4</issue><fpage>736</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.11.013</pub-id><pub-id pub-id-type="pmid">31786256</pub-id><pub-id pub-id-type="pmcid">PMC7085428</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arab</surname><given-names>JP</given-names></name><etal>et al</etal></person-group><article-title>An open-label, dose-escalation study to assess the safety and efficacy of IL-22 Agonist F-652 in patients with alcohol-associated hepatitis</article-title><source>Hepatology</source><year>2020</year><volume>72</volume><issue>2</issue><fpage>441</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1002/hep.31046</pub-id><pub-id pub-id-type="pmid">31774566</pub-id><pub-id pub-id-type="pmcid">PMC7250715</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szabo</surname><given-names>G</given-names></name><name name-style="western"><surname>Mandrekar</surname><given-names>P</given-names></name></person-group><article-title>A recent perspective on alcohol, immunity, and host defense</article-title><source>Alcohol Clin Exp Res</source><year>2009</year><volume>33</volume><issue>2</issue><fpage>220</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1111/j.1530-0277.2008.00842.x</pub-id><pub-id pub-id-type="pmid">19053973</pub-id><pub-id pub-id-type="pmcid">PMC3787826</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>RS</given-names></name><etal>et al</etal></person-group><article-title>The role of neutrophils in alcohol-related hepatitis</article-title><source>J Hepatol</source><year>2023</year><volume>79</volume><issue>4</issue><fpage>1037</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.05.017</pub-id><pub-id pub-id-type="pmid">37290590</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcohol-associated hepatitis</article-title><source>J Hepatol</source><year>2023</year><volume>78</volume><issue>1</issue><fpage>28</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2022.08.029</pub-id><pub-id pub-id-type="pmid">36063965</pub-id><pub-id pub-id-type="pmcid">PMC11910133</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehal</surname><given-names>W</given-names></name></person-group><article-title>Mechanisms of liver fibrosis in metabolic syndrome</article-title><source>eGastroenterology</source><year>2023</year><volume>1</volume><issue>1</issue><elocation-id>e100015</elocation-id><pub-id pub-id-type="doi">10.1136/egastro-2023-100015</pub-id><pub-id pub-id-type="pmid">37946713</pub-id><pub-id pub-id-type="pmcid">PMC10634657</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Distinct histopathological phenotypes of severe alcoholic hepatitis suggest different mechanisms driving liver injury and failure</article-title><source>J Clin Invest</source><year>2022</year><volume>132</volume><issue>14</issue><elocation-id>e157780</elocation-id><pub-id pub-id-type="doi">10.1172/JCI157780</pub-id><pub-id pub-id-type="pmid">35838051</pub-id><pub-id pub-id-type="pmcid">PMC9282929</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadi</surname><given-names>AR</given-names></name><etal>et al</etal></person-group><article-title>Discovery and characterization of cross-reactive intrahepatic antibodies in severe alcoholic hepatitis</article-title><source>Elife</source><year>2023</year><volume>12</volume><elocation-id>RP86678</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.86678.2</pub-id><pub-id pub-id-type="pmid">38055614</pub-id><pub-id pub-id-type="pmcid">PMC10699809</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louvet</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials</article-title><source>Gastroenterology</source><year>2018</year><volume>155</volume><issue>2</issue><fpage>458</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.05.011</pub-id><pub-id pub-id-type="pmid">29738698</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boetticher</surname><given-names>NC</given-names></name><etal>et al</etal></person-group><article-title>A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis</article-title><source>Gastroenterology</source><year>2008</year><volume>135</volume><issue>6</issue><fpage>1953</fpage><lpage>1960</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.08.057</pub-id><pub-id pub-id-type="pmid">18848937</pub-id><pub-id pub-id-type="pmcid">PMC2639749</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szabo</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis</article-title><source>Hepatology</source><year>2022</year><volume>76</volume><issue>4</issue><fpage>1058</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1002/hep.32478</pub-id><pub-id pub-id-type="pmid">35340032</pub-id><pub-id pub-id-type="pmcid">PMC10062003</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akriviadis</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial</article-title><source>Gastroenterology</source><year>2000</year><volume>119</volume><issue>6</issue><fpage>1637</fpage><lpage>1648</lpage><pub-id pub-id-type="doi">10.1053/gast.2000.20189</pub-id><pub-id pub-id-type="pmid">11113085</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krenkel</surname><given-names>O</given-names></name><etal>et al</etal></person-group><article-title>Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><issue>4</issue><fpage>1270</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1002/hep.29544</pub-id><pub-id pub-id-type="pmid">28940700</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ambade</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice</article-title><source>Hepatology</source><year>2019</year><volume>69</volume><issue>3</issue><fpage>1105</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1002/hep.30249</pub-id><pub-id pub-id-type="pmid">30179264</pub-id><pub-id pub-id-type="pmcid">PMC6393202</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Monocyte-derived macrophages orchestrate multiple cell-type interactions to repair necrotic liver lesions in disease models</article-title><source>J Clin Invest</source><year>2023</year><volume>133</volume><issue>15</issue><elocation-id>e166954</elocation-id><pub-id pub-id-type="doi">10.1172/JCI166954</pub-id><pub-id pub-id-type="pmid">37338984</pub-id><pub-id pub-id-type="pmcid">PMC10378165</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guillot</surname><given-names>A,</given-names></name> and Tacke F</person-group><article-title>Spatial dimension of macrophage heterogeneity in liver diseases</article-title><source>eGastroenterology</source><year>2023</year><volume>1</volume><issue>1</issue><elocation-id>e000003</elocation-id><pub-id pub-id-type="doi">10.1136/egastro-2023-000003</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47<sup>phox</sup>-oxidative stress pathway in neutrophils</article-title><source>Gut</source><year>2017</year><volume>66</volume><issue>4</issue><fpage>705</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2016-311861</pub-id><pub-id pub-id-type="pmid">27679493</pub-id><pub-id pub-id-type="pmcid">PMC5458746</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertola</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: a critical role for E-selectin</article-title><source>Hepatology</source><year>2013</year><volume>58</volume><issue>5</issue><fpage>1814</fpage><lpage>1823</lpage><pub-id pub-id-type="doi">10.1002/hep.26419</pub-id><pub-id pub-id-type="pmid">23532958</pub-id><pub-id pub-id-type="pmcid">PMC3726575</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wieser</surname><given-names>V</given-names></name><etal>et al</etal></person-group><article-title>Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors</article-title><source>Gut</source><year>2017</year><volume>66</volume><issue>5</issue><fpage>930</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2015-310344</pub-id><pub-id pub-id-type="pmid">26858343</pub-id><pub-id pub-id-type="pmcid">PMC5531226</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>French</surname><given-names>SW</given-names></name><etal>et al</etal></person-group><article-title>The role of the IL-8 signaling pathway in the infiltration of granulocytes into the livers of patients with alcoholic hepatitis</article-title><source>Exp Mol Pathol</source><year>2017</year><volume>103</volume><issue>2</issue><fpage>137</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.yexmp.2017.08.005</pub-id><pub-id pub-id-type="pmid">28818508</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maccioni</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Alcohol-associated bowel disease: new insights into pathogenesis</article-title><source>eGastroenterology</source><year>2023</year><volume>1</volume><issue>1</issue><elocation-id>e100013</elocation-id><pub-id pub-id-type="doi">10.1136/egastro-2023-100013</pub-id><pub-id pub-id-type="pmid">37662449</pub-id><pub-id pub-id-type="pmcid">PMC10472976</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>JT</given-names></name></person-group><article-title>Pathophysiology of inflammatory bowel diseases</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>27</issue><fpage>2652</fpage><lpage>2664</lpage><pub-id pub-id-type="doi">10.1056/NEJMra2002697</pub-id><pub-id pub-id-type="pmid">33382932</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripathi</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>The gut-liver axis and the intersection with the microbiome</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2018</year><volume>15</volume><issue>7</issue><fpage>397</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1038/s41575-018-0011-z</pub-id><pub-id pub-id-type="pmid">29748586</pub-id><pub-id pub-id-type="pmcid">PMC6319369</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassard</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ciocan</surname><given-names>D</given-names></name></person-group><article-title>Microbiota, a key player in alcoholic liver disease</article-title><source>Clin Mol Hepatol</source><year>2018</year><volume>24</volume><issue>2</issue><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.3350/cmh.2017.0067</pub-id><pub-id pub-id-type="pmid">29268595</pub-id><pub-id pub-id-type="pmcid">PMC6038939</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mutlu</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats</article-title><source>Alcohol Clin Exp Res</source><year>2009</year><volume>33</volume><issue>10</issue><fpage>1836</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.1111/j.1530-0277.2009.01022.x</pub-id><pub-id pub-id-type="pmid">19645728</pub-id><pub-id pub-id-type="pmcid">PMC3684271</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>AW</given-names></name><etal>et al</etal></person-group><article-title>Enteric dysbiosis associated with a mouse model of alcoholic liver disease</article-title><source>Hepatology</source><year>2011</year><volume>53</volume><issue>1</issue><fpage>96</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1002/hep.24018</pub-id><pub-id pub-id-type="pmid">21254165</pub-id><pub-id pub-id-type="pmcid">PMC3059122</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease</article-title><source>Nature</source><year>2019</year><volume>575</volume><issue>7783</issue><fpage>505</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1742-x</pub-id><pub-id pub-id-type="pmid">31723265</pub-id><pub-id pub-id-type="pmcid">PMC6872939</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartmann</surname><given-names>P</given-names></name><name name-style="western"><surname>Schnabl</surname><given-names>B</given-names></name></person-group><article-title>Fungal infections and the fungal microbiome in hepatobiliary disorders</article-title><source>J Hepatol</source><year>2023</year><volume>78</volume><issue>4</issue><fpage>836</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2022.12.006</pub-id><pub-id pub-id-type="pmid">36565724</pub-id><pub-id pub-id-type="pmcid">PMC10033447</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Intestinal virome in patients with alcoholic hepatitis</article-title><source>Hepatology</source><year>2020</year><volume>72</volume><issue>6</issue><fpage>2182</fpage><lpage>2196</lpage><pub-id pub-id-type="doi">10.1002/hep.31459</pub-id><pub-id pub-id-type="pmid">32654263</pub-id><pub-id pub-id-type="pmcid">PMC8159727</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohashi</surname><given-names>W</given-names></name><etal>et al</etal></person-group><article-title>Maintenance of intestinal epithelial homeostasis by zinc transporters</article-title><source>Dig Dis Sci</source><year>2019</year><volume>64</volume><issue>9</issue><fpage>2404</fpage><lpage>2415</lpage><pub-id pub-id-type="doi">10.1007/s10620-019-05561-2</pub-id><pub-id pub-id-type="pmid">30830525</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iritani</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>The useful predictors of zinc deficiency for the management of chronic liver disease</article-title><source>J Gastroenterol</source><year>2022</year><volume>57</volume><issue>4</issue><fpage>322</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1007/s00535-022-01852-0</pub-id><pub-id pub-id-type="pmid">35233650</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>W</given-names></name><etal>et al</etal></person-group><article-title>Paneth cell dysfunction mediates alcohol-related steatohepatitis through promoting bacterial translocation in mice: role of zinc deficiency</article-title><source>Hepatology</source><year>2020</year><volume>71</volume><issue>5</issue><fpage>1575</fpage><lpage>1591</lpage><pub-id pub-id-type="doi">10.1002/hep.30945</pub-id><pub-id pub-id-type="pmid">31520476</pub-id><pub-id pub-id-type="pmcid">PMC7069794</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parks</surname><given-names>OB</given-names></name><etal>et al</etal></person-group><article-title>Interleukin-22 signaling in the regulation of intestinal health and disease</article-title><source>Front Cell Dev Biol</source><year>2016</year><volume>3</volume><elocation-id>85</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2015.00085</pub-id><pub-id pub-id-type="pmid">26793707</pub-id><pub-id pub-id-type="pmcid">PMC4710696</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendrikx</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice</article-title><source>Gut</source><year>2019</year><volume>68</volume><issue>8</issue><fpage>1504</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-317232</pub-id><pub-id pub-id-type="pmid">30448775</pub-id><pub-id pub-id-type="pmcid">PMC6387784</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kouno</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Engineered bacteria producing aryl-hydrocarbon receptor agonists protect against ethanol-induced liver disease in mice</article-title><source>Alcohol Clin Exp Res (Hoboken)</source><year>2023</year><volume>47</volume><issue>5</issue><fpage>856</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1111/acer.15048</pub-id><pub-id pub-id-type="pmid">36871955</pub-id><pub-id pub-id-type="pmcid">PMC10795770</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Aryl hydrocarbon receptor deficiency in intestinal epithelial cells aggravates alcohol-related liver disease</article-title><source>Cell Mol Gastroenterol Hepatol</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>233</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2021.08.014</pub-id><pub-id pub-id-type="pmid">34454169</pub-id><pub-id pub-id-type="pmcid">PMC8599170</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wrzosek</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury</article-title><source>Gut</source><year>2021</year><volume>70</volume><issue>7</issue><fpage>1299</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-321565</pub-id><pub-id pub-id-type="pmid">33004548</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ranjbarian</surname><given-names>T</given-names></name><name name-style="western"><surname>Schnabl</surname><given-names>B</given-names></name></person-group><article-title>Gut microbiome-centered therapies for alcohol-associated liver disease</article-title><source>Semin Liver Dis</source><year>2023</year><volume>43</volume><issue>3</issue><fpage>311</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1055/a-2145-7331</pub-id><pub-id pub-id-type="pmid">37527781</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pande</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial</article-title><source>Hepatol Int</source><year>2023</year><volume>17</volume><issue>1</issue><fpage>249</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1007/s12072-022-10438-0</pub-id><pub-id pub-id-type="pmid">36469298</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>JS</given-names></name><etal>et al</etal></person-group><article-title>Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial</article-title><source>Hepatology</source><year>2017</year><volume>66</volume><issue>6</issue><fpage>1727</fpage><lpage>1738</lpage><pub-id pub-id-type="doi">10.1002/hep.29306</pub-id><pub-id pub-id-type="pmid">28586116</pub-id><pub-id pub-id-type="pmcid">PMC6102730</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloom</surname><given-names>PP</given-names></name><etal>et al</etal></person-group><article-title>Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient</article-title><source>Hepatol Commun</source><year>2022</year><volume>6</volume><issue>8</issue><fpage>2079</fpage><lpage>2089</lpage><pub-id pub-id-type="doi">10.1002/hep4.1950</pub-id><pub-id pub-id-type="pmid">35384391</pub-id><pub-id pub-id-type="pmcid">PMC9315114</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanahan</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>The healthy microbiome-what is the definition of a healthy gut microbiome?</article-title><source>Gastroenterology</source><year>2021</year><volume>160</volume><issue>2</issue><fpage>483</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.09.057</pub-id><pub-id pub-id-type="pmid">33253682</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Ductular reaction in liver diseases: pathological mechanisms and translational significances</article-title><source>Hepatology</source><year>2019</year><volume>69</volume><issue>1</issue><fpage>420</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1002/hep.30150</pub-id><pub-id pub-id-type="pmid">30070383</pub-id><pub-id pub-id-type="pmcid">PMC6324973</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Persistent mTORC1 activation due to loss of liver tuberous sclerosis complex 1 promotes liver injury in alcoholic hepatitis</article-title><source>Hepatology</source><year>2023</year><volume>78</volume><issue>2</issue><fpage>503</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1097/HEP.0000000000000373</pub-id><pub-id pub-id-type="pmid">36999531</pub-id><pub-id pub-id-type="pmcid">PMC10363242</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El&#223;ner</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Nuclear translocation of RELB is increased in diseased human liver and promotes ductular reaction and biliary fibrosis in mice</article-title><source>Gastroenterology</source><year>2019</year><volume>156</volume><issue>4</issue><fpage>1190</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.11.018</pub-id><pub-id pub-id-type="pmid">30445013</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguilar-Bravo</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis</article-title><source>Hepatology</source><year>2019</year><volume>69</volume><issue>5</issue><fpage>2180</fpage><lpage>2195</lpage><pub-id pub-id-type="doi">10.1002/hep.30472</pub-id><pub-id pub-id-type="pmid">30565271</pub-id><pub-id pub-id-type="pmcid">PMC9189898</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguilar-Bravo</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming</article-title><source>J Hepatol</source><year>2023</year><volume>79</volume><issue>3</issue><fpage>728</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.04.013</pub-id><pub-id pub-id-type="pmid">37088308</pub-id><pub-id pub-id-type="pmcid">PMC10540088</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guillot</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression</article-title><source>Hepatology</source><year>2023</year><volume>78</volume><issue>1</issue><fpage>150</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1097/HEP.0000000000000270</pub-id><pub-id pub-id-type="pmid">36630995</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ari&#241;o</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Ductular reaction-associated neutrophils promote biliary epithelium proliferation in chronic liver disease</article-title><source>J Hepatol</source><year>2023</year><volume>79</volume><issue>4</issue><fpage>1025</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.05.045</pub-id><pub-id pub-id-type="pmid">37348790</pub-id><pub-id pub-id-type="pmcid">PMC10585421</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mTORC1 activation and defective autophagy</article-title><source>J Hepatol</source><year>2022</year><volume>76</volume><issue>3</issue><fpage>639</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.10.014</pub-id><pub-id pub-id-type="pmid">34710483</pub-id><pub-id pub-id-type="pmcid">PMC8858859</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navarro-Corcuera</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Long non-coding RNA ACTA2-AS1 promotes ductular reaction by interacting with the p300/ELK1 complex</article-title><source>J Hepatol</source><year>2022</year><volume>76</volume><issue>4</issue><fpage>921</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.12.014</pub-id><pub-id pub-id-type="pmid">34953958</pub-id><pub-id pub-id-type="pmcid">PMC8934273</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal>et al</etal></person-group><article-title>Biliary NIK promotes ductular reaction and liver injury and fibrosis in mice</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><elocation-id>5111</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-32575-8</pub-id><pub-id pub-id-type="pmid">36042192</pub-id><pub-id pub-id-type="pmcid">PMC9427946</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackowiak</surname><given-names>B</given-names></name><name name-style="western"><surname>Gao</surname><given-names>B</given-names></name></person-group><article-title>Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction</article-title><source>Hepatology</source><year>2023</year><volume>78</volume><issue>2</issue><fpage>378</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1097/HEP.0000000000000416</pub-id><pub-id pub-id-type="pmid">37078452</pub-id><pub-id pub-id-type="pmcid">PMC10524099</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nassir</surname><given-names>F</given-names></name><name name-style="western"><surname>Ibdah</surname><given-names>JA</given-names></name></person-group><article-title>Role of mitochondria in alcoholic liver disease</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><issue>9</issue><fpage>2136</fpage><lpage>2142</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i9.2136</pub-id><pub-id pub-id-type="pmid">24605012</pub-id><pub-id pub-id-type="pmcid">PMC3942818</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Role and mechanisms of mitophagy in liver diseases</article-title><source>Cells</source><year>2020</year><volume>9</volume><issue>4</issue><elocation-id>837</elocation-id><pub-id pub-id-type="doi">10.3390/cells9040837</pub-id><pub-id pub-id-type="pmid">32244304</pub-id><pub-id pub-id-type="pmcid">PMC7226762</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruguera</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Giant mitochondria in hepatocytes: a diagnostic hint for alcoholic liver disease</article-title><source>Gastroenterology</source><year>1977</year><volume>73</volume><issue>6</issue><fpage>1383</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(19)31518-5</pub-id><pub-id pub-id-type="pmid">913978</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation</article-title><source>Hepatology</source><year>2023</year><volume>77</volume><issue>1</issue><fpage>159</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1002/hep.32604</pub-id><pub-id pub-id-type="pmid">35698731</pub-id><pub-id pub-id-type="pmcid">PMC9744966</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1-TFAM signalling in alcoholic steatohepatitis</article-title><source>Gut</source><year>2021</year><volume>70</volume><issue>10</issue><fpage>1933</fpage><lpage>1945</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-321548</pub-id><pub-id pub-id-type="pmid">33177163</pub-id><pub-id pub-id-type="pmcid">PMC8110597</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2018</year><volume>15</volume><issue>1</issue><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2017.116</pub-id><pub-id pub-id-type="pmid">28930290</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathur</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Adipose lipolysis is important for ethanol to induce fatty liver in the National Institute on Alcohol Abuse and Alcoholism murine model of chronic and binge ethanol feeding</article-title><source>Hepatology</source><year>2023</year><volume>77</volume><issue>5</issue><fpage>1688</fpage><lpage>1701</lpage><pub-id pub-id-type="doi">10.1002/hep.32675</pub-id><pub-id pub-id-type="pmid">35844150</pub-id><pub-id pub-id-type="pmcid">PMC9845426</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singal</surname><given-names>AK</given-names></name><etal>et al</etal></person-group><article-title>Emerging targets for therapy in ALD: Lessons from NASH</article-title><comment>[published online March 21, 2023].</comment><source>Hepatology</source><pub-id pub-id-type="doi">10.1097/hep.0000000000000381</pub-id><pub-id pub-id-type="pmid">36938877</pub-id><pub-id pub-id-type="pmcid">PMC10511666</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassanein</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Safety, pharmacokinetics, and efficacy signals of larsucosterol (DUR-928) in alcohol-associated hepatitis</article-title><comment>[published online May 8, 2023].</comment><source>Am J Gastroenterol</source><pub-id pub-id-type="doi">10.14309/ajg.0000000000002275</pub-id><pub-id pub-id-type="pmid">37011138</pub-id><pub-id pub-id-type="pmcid">PMC10758349</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen-Khac</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>19</issue><fpage>1781</fpage><lpage>1789</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1101214</pub-id><pub-id pub-id-type="pmid">22070475</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis</article-title><source>J Hepatol</source><year>2007</year><volume>47</volume><issue>2</issue><fpage>277</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2007.03.027</pub-id><pub-id pub-id-type="pmid">17532088</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higuera-de la Tijera</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis</article-title><source>Ann Hepatol</source><year>2014</year><volume>13</volume><issue>3</issue><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/S1665-2681(19)30863-4</pub-id><pub-id pub-id-type="pmid">24756009</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ding</surname><given-names>WX</given-names></name></person-group><article-title>Role of autophagy in alcohol and drug-induced liver injury</article-title><source>Food Chem Toxicol</source><year>2020</year><volume>136</volume><elocation-id>111075</elocation-id><pub-id pub-id-type="doi">10.1016/j.fct.2019.111075</pub-id><pub-id pub-id-type="pmid">31877367</pub-id><pub-id pub-id-type="pmcid">PMC6947668</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>X</given-names></name><name name-style="western"><surname>Ding</surname><given-names>WX</given-names></name></person-group><article-title>Role and mechanisms of autophagy in alcohol-induced liver injury</article-title><source>Adv Pharmacol</source><year>2019</year><volume>85</volume><fpage>109</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/bs.apha.2019.01.008</pub-id><pub-id pub-id-type="pmid">31307584</pub-id><pub-id pub-id-type="pmcid">PMC7141786</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Autophagy in liver diseases: A review</article-title><source>Mol Aspects Med</source><year>2021</year><volume>82</volume><elocation-id>100973</elocation-id><pub-id pub-id-type="doi">10.1016/j.mam.2021.100973</pub-id><pub-id pub-id-type="pmid">34120768</pub-id><pub-id pub-id-type="pmcid">PMC9585624</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases</article-title><source>Gut</source><year>2021</year><volume>70</volume><issue>4</issue><fpage>784</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-322526</pub-id><pub-id pub-id-type="pmid">33127832</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buch</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis</article-title><source>Nat Genet</source><year>2015</year><volume>47</volume><issue>12</issue><fpage>1443</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1038/ng.3417</pub-id><pub-id pub-id-type="pmid">26482880</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Innes</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Genome-wide association study for alcohol-related cirrhosis identifies risk loci in MARC1 and HNRNPUL1</article-title><source>Gastroenterology</source><year>2020</year><volume>159</volume><issue>4</issue><fpage>1276</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.06.014</pub-id><pub-id pub-id-type="pmid">32561361</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tr&#233;po</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease</article-title><source>J Hepatol</source><year>2011</year><volume>55</volume><issue>4</issue><fpage>906</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2011.01.028</pub-id><pub-id pub-id-type="pmid">21334404</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abul-Husn</surname><given-names>NS</given-names></name><etal>et al</etal></person-group><article-title>A protein-truncating HSD17B13 variant and protection from chronic liver disease</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><issue>12</issue><fpage>1096</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1712191</pub-id><pub-id pub-id-type="pmid">29562163</pub-id><pub-id pub-id-type="pmcid">PMC6668033</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Variant in PNPLA3 is associated with alcoholic liver disease</article-title><source>Nat Genet</source><year>2010</year><volume>42</volume><issue>1</issue><fpage>21</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/ng.488</pub-id><pub-id pub-id-type="pmid">19946271</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaudoin</surname><given-names>JJ</given-names></name><etal>et al</etal></person-group><article-title>An exploratory genome-wide analysis of genetic risk for alcoholic hepatitis</article-title><source>Scand J Gastroenterol</source><year>2017</year><volume>52</volume><issue>11</issue><fpage>1263</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1080/00365521.2017.1359664</pub-id><pub-id pub-id-type="pmid">28776448</pub-id><pub-id pub-id-type="pmcid">PMC5773288</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwantes-An</surname><given-names>TH</given-names></name><etal>et al</etal></person-group><article-title>Genome-wide association study and meta-analysis on alcohol-associated liver cirrhosis identifies genetic risk factors</article-title><source>Hepatology</source><year>2021</year><volume>73</volume><issue>5</issue><fpage>1920</fpage><lpage>1931</lpage><pub-id pub-id-type="doi">10.1002/hep.31535</pub-id><pub-id pub-id-type="pmid">32853455</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deaciuc</surname><given-names>IV</given-names></name><etal>et al</etal></person-group><article-title>Large-scale gene profiling of the liver in a mouse model of chronic, intragastric ethanol infusion</article-title><source>J Hepatol</source><year>2004</year><volume>40</volume><issue>2</issue><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2003.10.021</pub-id><pub-id pub-id-type="pmid">14739091</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aff&#242;</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis</article-title><source>Gut</source><year>2013</year><volume>62</volume><issue>3</issue><fpage>452</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2011-301146</pub-id><pub-id pub-id-type="pmid">22637703</pub-id><pub-id pub-id-type="pmcid">PMC4064940</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>M-J</given-names></name><etal>et al</etal></person-group><article-title>Fat-specific protein 27/CIDEC promotes development of alcoholic steatohepatitis in mice and humans</article-title><source>Gastroenterology</source><year>2015</year><volume>149</volume><issue>4</issue><fpage>1030</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.06.009</pub-id><pub-id pub-id-type="pmid">26099526</pub-id><pub-id pub-id-type="pmcid">PMC4584194</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><etal>et al</etal></person-group><article-title>The role of SHP/REV-ERB&#945;/CYP4A axis in the pathogenesis of alcohol-associated liver disease</article-title><source>JCI Insight</source><year>2021</year><volume>6</volume><issue>16</issue><elocation-id>e140687</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.140687</pub-id><pub-id pub-id-type="pmid">34423788</pub-id><pub-id pub-id-type="pmcid">PMC8410014</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Primary alcohol-activated human and mouse hepatic stellate cells share similarities in gene-expression profiles</article-title><source>Hepatol Commun</source><year>2020</year><volume>4</volume><issue>4</issue><fpage>606</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1002/hep4.1483</pub-id><pub-id pub-id-type="pmid">32258954</pub-id><pub-id pub-id-type="pmcid">PMC7109347</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Transcriptomic profiling identifies novel hepatic and intestinal genes following chronic plus binge ethanol feeding in mice</article-title><source>Dig Dis Sci</source><year>2020</year><volume>65</volume><issue>12</issue><fpage>3592</fpage><lpage>3604</lpage><pub-id pub-id-type="doi">10.1007/s10620-020-06461-6</pub-id><pub-id pub-id-type="pmid">32671585</pub-id><pub-id pub-id-type="pmcid">PMC7669632</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Single-cell RNA transcriptome profiling of liver cells of short-term alcoholic liver injury in mice</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>5</issue><elocation-id>4344</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24054344</pub-id><pub-id pub-id-type="pmid">36901774</pub-id><pub-id pub-id-type="pmcid">PMC10002329</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanova</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><issue>5</issue><fpage>1737</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1002/hep.29645</pub-id><pub-id pub-id-type="pmid">29108122</pub-id><pub-id pub-id-type="pmcid">PMC5906140</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argemi</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><elocation-id>3126</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-11004-3</pub-id><pub-id pub-id-type="pmid">31311938</pub-id><pub-id pub-id-type="pmcid">PMC6635373</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Noninvasive proteomic biomarkers for alcohol-related liver disease</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><issue>6</issue><fpage>1277</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01850-y</pub-id><pub-id pub-id-type="pmid">35654907</pub-id><pub-id pub-id-type="pmcid">PMC9205783</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argemi</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Integrated transcriptomic and proteomic analysis identifies plasma biomarkers of hepatocellular failure in alcohol-associated hepatitis</article-title><source>Am J Pathol</source><year>2022</year><volume>192</volume><issue>12</issue><fpage>1658</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2022.08.009</pub-id><pub-id pub-id-type="pmid">36243044</pub-id><pub-id pub-id-type="pmcid">PMC9765311</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><etal>et al</etal></person-group><article-title>LncRNA AK054921 and AK128652 are potential serum biomarkers and predictors of patient survival with alcoholic cirrhosis</article-title><source>Hepatol Commun</source><year>2017</year><volume>1</volume><issue>6</issue><fpage>513</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1002/hep4.1061</pub-id><pub-id pub-id-type="pmid">29104954</pub-id><pub-id pub-id-type="pmcid">PMC5665385</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rachakonda</surname><given-names>V</given-names></name><etal>et al</etal></person-group><article-title>Serum metabolomic profiling in acute alcoholic hepatitis identifies multiple dysregulated pathways</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>12</issue><elocation-id>e113860</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0113860</pub-id><pub-id pub-id-type="pmid">25461442</pub-id><pub-id pub-id-type="pmcid">PMC4252257</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Massey</surname><given-names>V</given-names></name><etal>et al</etal></person-group><article-title>Integrated multiomics reveals glucose use reprogramming and identifies a novel hexokinase in alcoholic hepatitis</article-title><source>Gastroenterology</source><year>2021</year><volume>160</volume><issue>5</issue><fpage>1725</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.12.008</pub-id><pub-id pub-id-type="pmid">33309778</pub-id><pub-id pub-id-type="pmcid">PMC8613537</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luther</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>The circulating proteomic signature of alcohol-associated liver disease</article-title><source>JCI Insight</source><year>2022</year><volume>7</volume><issue>14</issue><elocation-id>e159775</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.159775</pub-id><pub-id pub-id-type="pmid">35866482</pub-id><pub-id pub-id-type="pmcid">PMC9431701</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Listopad</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Differentiating between liver diseases by applying multiclass machine learning approaches to transcriptomics of liver tissue or blood-based samples</article-title><source>JHEP Rep</source><year>2022</year><volume>4</volume><issue>10</issue><elocation-id>100560</elocation-id><pub-id pub-id-type="doi">10.1016/j.jhepr.2022.100560</pub-id><pub-id pub-id-type="pmid">36119721</pub-id><pub-id pub-id-type="pmcid">PMC9472076</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>PS</given-names></name><etal>et al</etal></person-group><article-title>Proteomic analysis of alcohol-associated hepatitis reveals glycoprotein NMB (GPNMB) as a novel hepatic and serum biomarker</article-title><source>Alcohol</source><year>2022</year><volume>99</volume><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.alcohol.2021.11.005</pub-id><pub-id pub-id-type="pmid">34923085</pub-id><pub-id pub-id-type="pmcid">PMC8919678</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardesty</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Hepatic protein and phosphoprotein signatures of alcohol-associated cirrhosis and hepatitis</article-title><source>Am J Pathol</source><year>2022</year><volume>192</volume><issue>7</issue><fpage>1066</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2022.04.004</pub-id><pub-id pub-id-type="pmid">35490715</pub-id><pub-id pub-id-type="pmcid">PMC9253914</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eguchi</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood</article-title><source>Hepatology</source><year>2017</year><volume>65</volume><issue>2</issue><fpage>475</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1002/hep.28838</pub-id><pub-id pub-id-type="pmid">27639178</pub-id><pub-id pub-id-type="pmcid">PMC5407075</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tr&#233;po</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Combination of gene expression signature and model for end-stage liver disease score predicts survival of patients with severe alcoholic hepatitis</article-title><source>Gastroenterology</source><year>2018</year><volume>154</volume><issue>4</issue><fpage>965</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2017.10.048</pub-id><pub-id pub-id-type="pmid">29158192</pub-id><pub-id pub-id-type="pmcid">PMC5847453</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balog</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Emergence of highly profibrotic and proinflammatory Lrat+Fbln2+ HSC subpopulation in alcoholic hepatitis</article-title><source>Hepatology</source><year>2023</year><volume>78</volume><issue>1</issue><fpage>212</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1002/hep.32793</pub-id><pub-id pub-id-type="pmid">36181700</pub-id><pub-id pub-id-type="pmcid">PMC10977045</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramachandran</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Resolving the fibrotic niche of human liver cirrhosis at single-cell level</article-title><source>Nature</source><year>2019</year><volume>575</volume><issue>7783</issue><fpage>512</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1631-3</pub-id><pub-id pub-id-type="pmid">31597160</pub-id><pub-id pub-id-type="pmcid">PMC6876711</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bou Saleh</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis</article-title><source>J Hepatol</source><year>2021</year><volume>75</volume><issue>4</issue><fpage>912</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.05.041</pub-id><pub-id pub-id-type="pmid">34129887</pub-id><pub-id pub-id-type="pmcid">PMC11868489</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weichselbaum</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Epigenetic basis for monocyte dysfunction in patients with severe alcoholic hepatitis</article-title><source>J Hepatol</source><year>2020</year><volume>73</volume><issue>2</issue><fpage>303</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.02.017</pub-id><pub-id pub-id-type="pmid">32145259</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><elocation-id>4560</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-24843-w</pub-id><pub-id pub-id-type="pmid">34315876</pub-id><pub-id pub-id-type="pmcid">PMC8316465</pub-id></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyun</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Epithelial splicing regulatory protein 2-mediated alternative splicing reprograms hepatocytes in severe alcoholic hepatitis</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><issue>4</issue><fpage>2129</fpage><lpage>2145</lpage><pub-id pub-id-type="doi">10.1172/JCI132691</pub-id><pub-id pub-id-type="pmid">31945016</pub-id><pub-id pub-id-type="pmcid">PMC7108908</pub-id></element-citation></ref><ref id="B126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis</article-title><source>Hepatology</source><year>2023</year><volume>78</volume><issue>5</issue><fpage>1506</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1097/HEP.0000000000000433</pub-id><pub-id pub-id-type="pmid">37129868</pub-id><pub-id pub-id-type="pmcid">PMC10592686</pub-id></element-citation></ref><ref id="B127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guillot</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Deciphering the immune microenvironment on a single archival formalin-fixed paraffin-embedded tissue section by an immediately implementable multiplex fluorescence immunostaining protocol</article-title><source>Cancers (Basel)</source><year>2020</year><volume>12</volume><issue>9</issue><elocation-id>2449</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12092449</pub-id><pub-id pub-id-type="pmid">32872334</pub-id><pub-id pub-id-type="pmcid">PMC7565194</pub-id></element-citation></ref><ref id="B128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guillot</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Bile acid-activated macrophages promote biliary epithelial cell proliferation through integrin &#945;v&#946;6 upregulation following liver injury</article-title><source>J Clin Invest</source><year>2021</year><volume>131</volume><issue>9</issue><elocation-id>e132305</elocation-id><pub-id pub-id-type="doi">10.1172/JCI132305</pub-id><pub-id pub-id-type="pmid">33724957</pub-id><pub-id pub-id-type="pmcid">PMC8087210</pub-id></element-citation></ref><ref id="B129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsukamoto</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Intragastric ethanol infusion model in rodents</article-title><source>Methods Mol Biol</source><year>2008</year><volume>447</volume><fpage>33</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1007/978-1-59745-242-7_3</pub-id><pub-id pub-id-type="pmid">18369909</pub-id></element-citation></ref><ref id="B130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandon-Warner</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Rodent models of alcoholic liver disease: of mice and men</article-title><source>Alcohol</source><year>2012</year><volume>46</volume><issue>8</issue><fpage>715</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/j.alcohol.2012.08.004</pub-id><pub-id pub-id-type="pmid">22960051</pub-id><pub-id pub-id-type="pmcid">PMC3496818</pub-id></element-citation></ref><ref id="B131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lieber</surname><given-names>CS</given-names></name><etal>et al</etal></person-group><article-title>Experimental methods of ethanol administration</article-title><source>Hepatology</source><year>1989</year><volume>10</volume><issue>4</issue><fpage>501</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1002/hep.1840100417</pub-id><pub-id pub-id-type="pmid">2673971</pub-id></element-citation></ref><ref id="B132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueno</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Mouse intragastric infusion (iG) model</article-title><source>Nat Protoc</source><year>2012</year><volume>7</volume><issue>4</issue><fpage>771</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.014</pub-id><pub-id pub-id-type="pmid">22461066</pub-id><pub-id pub-id-type="pmcid">PMC4197794</pub-id></element-citation></ref><ref id="B133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertola</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Mouse model of chronic and binge ethanol feeding (the NIAAA model)</article-title><source>Nat Protoc</source><year>2013</year><volume>8</volume><issue>3</issue><fpage>627</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.032</pub-id><pub-id pub-id-type="pmid">23449255</pub-id><pub-id pub-id-type="pmcid">PMC3788579</pub-id></element-citation></ref><ref id="B134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Experimental models of fatty liver diseases: Status and appraisal</article-title><source>Hepatol Commun</source><year>2023</year><volume>7</volume><issue>7</issue><elocation-id>e00200</elocation-id><pub-id pub-id-type="doi">10.1097/HC9.0000000000000200</pub-id><pub-id pub-id-type="pmid">37378635</pub-id><pub-id pub-id-type="pmcid">PMC10309509</pub-id></element-citation></ref><ref id="B135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Animal models of alcoholic liver disease: pathogenesis and clinical relevance</article-title><source>Gene Expr</source><year>2017</year><volume>17</volume><issue>3</issue><fpage>173</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.3727/105221617X695519</pub-id><pub-id pub-id-type="pmid">28411363</pub-id><pub-id pub-id-type="pmcid">PMC5500917</pub-id></element-citation></ref><ref id="B136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsukamoto</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>&#8220;Second hit&#8221; models of alcoholic liver disease</article-title><source>Semin Liver Dis</source><year>2009</year><volume>29</volume><issue>2</issue><fpage>178</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1055/s-0029-1214373</pub-id><pub-id pub-id-type="pmid">19387917</pub-id><pub-id pub-id-type="pmcid">PMC4197797</pub-id></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><etal>et al</etal></person-group><article-title>Neutrophil-hepatic stellate cell interactions promote fibrosis in experimental steatohepatitis</article-title><source>Cell Mol Gastroenterol Hepatol</source><year>2018</year><volume>5</volume><issue>3</issue><fpage>399</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2018.01.003</pub-id><pub-id pub-id-type="pmid">29552626</pub-id><pub-id pub-id-type="pmcid">PMC5852390</pub-id></element-citation></ref><ref id="B138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for CXCL1</article-title><source>Hepatology</source><year>2015</year><volume>62</volume><issue>4</issue><fpage>1070</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1002/hep.27921</pub-id><pub-id pub-id-type="pmid">26033752</pub-id><pub-id pub-id-type="pmcid">PMC4589443</pub-id></element-citation></ref><ref id="B139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>Y-T</given-names></name><etal>et al</etal></person-group><article-title>Single ethanol binge causes severe liver injury in mice fed Western diet</article-title><source>Hepatol Commun</source><year>2023</year><volume>7</volume><issue>7</issue><elocation-id>e00174</elocation-id><pub-id pub-id-type="doi">10.1097/HC9.0000000000000174</pub-id><pub-id pub-id-type="pmid">37314747</pub-id><pub-id pub-id-type="pmcid">PMC10270551</pub-id></element-citation></ref><ref id="B140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazaro</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice</article-title><source>Hepatology</source><year>2015</year><volume>61</volume><issue>1</issue><fpage>129</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1002/hep.27383</pub-id><pub-id pub-id-type="pmid">25132354</pub-id><pub-id pub-id-type="pmcid">PMC4280361</pub-id></element-citation></ref><ref id="B141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schonfeld</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>A Western diet with alcohol in drinking water recapitulates features of alcohol-associated liver disease in mice</article-title><source>Alcohol Clin Exp Res</source><year>2021</year><volume>45</volume><issue>10</issue><fpage>1980</fpage><lpage>1993</lpage><pub-id pub-id-type="doi">10.1111/acer.14700</pub-id><pub-id pub-id-type="pmid">34523155</pub-id><pub-id pub-id-type="pmcid">PMC9006178</pub-id></element-citation></ref><ref id="B142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buyco</surname><given-names>DG</given-names></name><etal>et al</etal></person-group><article-title>Concomitant Western diet and chronic-binge alcohol dysregulate hepatic metabolism</article-title><source>PLoS One</source><year>2023</year><volume>18</volume><issue>5</issue><elocation-id>e0281954</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0281954</pub-id><pub-id pub-id-type="pmid">37134024</pub-id><pub-id pub-id-type="pmcid">PMC10155975</pub-id></element-citation></ref><ref id="B143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rinella</surname><given-names>ME</given-names></name><etal>et al</etal></person-group><article-title>A multisociety Delphi consensus statement on new fatty liver disease nomenclature</article-title><source>J Hepatol</source><year>2023</year><volume>79</volume><issue>6</issue><fpage>1542</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.06.003</pub-id><pub-id pub-id-type="pmid">37364790</pub-id></element-citation></ref><ref id="B144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Israelsen</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>MetALD: new opportunities to understand the role of alcohol in steatotic liver disease</article-title><source>Lancet Gastroenterol Hepatol</source><year>2023</year><volume>8</volume><issue>10</issue><fpage>866</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(23)00206-6</pub-id><pub-id pub-id-type="pmid">37567208</pub-id></element-citation></ref><ref id="B145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;az</surname><given-names>LA</given-names></name><etal>et al</etal></person-group><article-title>The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2023</year><volume>20</volume><issue>12</issue><fpage>764</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1038/s41575-023-00822-y</pub-id><pub-id pub-id-type="pmid">37582985</pub-id></element-citation></ref><ref id="B146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vos</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019</article-title><source>Lancet</source><year>2020</year><volume>396</volume><issue>10258</issue><fpage>1204</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30925-9</pub-id><pub-id pub-id-type="pmid">33069326</pub-id><pub-id pub-id-type="pmcid">PMC7567026</pub-id></element-citation></ref><ref id="B147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tapper</surname><given-names>EB</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>ND</given-names></name></person-group><article-title>Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study</article-title><source>BMJ</source><year>2018</year><volume>362</volume><elocation-id>k2817</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.k2817</pub-id><pub-id pub-id-type="pmid">30021785</pub-id><pub-id pub-id-type="pmcid">PMC6050518</pub-id></element-citation></ref><ref id="B148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tapper</surname><given-names>EB</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>ND</given-names></name></person-group><article-title>Diagnosis and management of cirrhosis and its complications: a review</article-title><source>JAMA</source><year>2023</year><volume>329</volume><issue>18</issue><fpage>1589</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.5997</pub-id><pub-id pub-id-type="pmid">37159031</pub-id><pub-id pub-id-type="pmcid">PMC10843851</pub-id></element-citation></ref><ref id="B149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>DQ</given-names></name><etal>et al</etal></person-group><article-title>Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer</article-title><source>Cell Metab</source><year>2022</year><volume>34</volume><issue>7</issue><fpage>969</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2022.05.003</pub-id><pub-id pub-id-type="pmid">35793659</pub-id><pub-id pub-id-type="pmcid">PMC9762323</pub-id></element-citation></ref><ref id="B150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paik</surname><given-names>JM</given-names></name><etal>et al</etal></person-group><article-title>Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD</article-title><source>Hepatology</source><year>2020</year><volume>72</volume><issue>5</issue><fpage>1605</fpage><lpage>1616</lpage><pub-id pub-id-type="doi">10.1002/hep.31173</pub-id><pub-id pub-id-type="pmid">32043613</pub-id></element-citation></ref><ref id="B151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>DQ</given-names></name><etal>et al</etal></person-group><article-title>Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2023</year><volume>20</volume><issue>1</issue><fpage>37</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1038/s41575-022-00688-6</pub-id><pub-id pub-id-type="pmid">36258033</pub-id><pub-id pub-id-type="pmcid">PMC9579565</pub-id></element-citation></ref><ref id="B152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagstrom</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Risk of cancer in biopsy-proven alcohol-related liver disease: a population-based cohort study of 3410 Persons</article-title><source>Clin Gastroenterol Hepatol</source><year>2022</year><volume>20</volume><issue>4</issue><fpage>918</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2021.01.005</pub-id><pub-id pub-id-type="pmid">33421629</pub-id></element-citation></ref><ref id="B153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bucci</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome</article-title><source>Aliment Pharmacol Ther</source><year>2016</year><volume>43</volume><issue>3</issue><fpage>385</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1111/apt.13485</pub-id><pub-id pub-id-type="pmid">26662476</pub-id></element-citation></ref><ref id="B154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costentin</surname><given-names>CE</given-names></name><etal>et al</etal></person-group><article-title>Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study</article-title><source>Cancer</source><year>2018</year><volume>124</volume><issue>9</issue><fpage>1964</fpage><lpage>1972</lpage><pub-id pub-id-type="doi">10.1002/cncr.31215</pub-id><pub-id pub-id-type="pmid">29589878</pub-id></element-citation></ref><ref id="B155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costentin</surname><given-names>CE</given-names></name><etal>et al</etal></person-group><article-title>Geographical disparities of outcomes of hepatocellular carcinoma in france: the heavier burden of alcohol compared to hepatitis C</article-title><source>Dig Dis Sci</source><year>2020</year><volume>65</volume><issue>1</issue><fpage>301</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1007/s10620-019-05724-1</pub-id><pub-id pub-id-type="pmid">31346950</pub-id></element-citation></ref><ref id="B156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuper</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis</article-title><source>Hepatology</source><year>2001</year><volume>34</volume><issue>4 pt 1</issue><fpage>714</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1053/jhep.2001.28233</pub-id><pub-id pub-id-type="pmid">11584367</pub-id></element-citation></ref><ref id="B157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancebo</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups</article-title><source>Clin Gastroenterol Hepatol</source><year>2013</year><volume>11</volume><issue>1</issue><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2012.09.007</pub-id><pub-id pub-id-type="pmid">22982095</pub-id></element-citation></ref><ref id="B158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrero</surname><given-names>JA</given-names></name><etal>et al</etal></person-group><article-title>Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases</article-title><source>Hepatology</source><year>2018</year><volume>68</volume><issue>2</issue><fpage>723</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1002/hep.29913</pub-id><pub-id pub-id-type="pmid">29624699</pub-id></element-citation></ref><ref id="B159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kann</surname><given-names>AE</given-names></name><etal>et al</etal></person-group><article-title>Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study</article-title><source>Lancet Gastroenterol Hepatol</source><year>2023</year><volume>8</volume><issue>11</issue><fpage>1028</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(23)00192-9</pub-id><pub-id pub-id-type="pmid">37660703</pub-id></element-citation></ref><ref id="B160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandon-Warner</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Chronic ethanol feeding accelerates hepatocellular carcinoma progression in a sex-dependent manner in a mouse model of hepatocarcinogenesis</article-title><source>Alcohol Clin Exp Res</source><year>2012</year><volume>36</volume><issue>4</issue><fpage>641</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1111/j.1530-0277.2011.01660.x</pub-id><pub-id pub-id-type="pmid">22017344</pub-id><pub-id pub-id-type="pmcid">PMC3288433</pub-id></element-citation></ref><ref id="B161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trepo</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study</article-title><source>Lancet Oncol</source><year>2022</year><volume>23</volume><issue>1</issue><fpage>161</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00603-3</pub-id><pub-id pub-id-type="pmid">34902334</pub-id></element-citation></ref><ref id="B162"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meroni</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Genetic and epigenetic modifiers of alcoholic liver disease</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><issue>12</issue><elocation-id>3857</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19123857</pub-id><pub-id pub-id-type="pmid">30513996</pub-id><pub-id pub-id-type="pmcid">PMC6320903</pub-id></element-citation></ref><ref id="B163"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stickel</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis</article-title><source>Am J Gastroenterol</source><year>2018</year><volume>113</volume><issue>10</issue><fpage>1475</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1038/s41395-018-0041-8</pub-id><pub-id pub-id-type="pmid">29535416</pub-id></element-citation></ref><ref id="B164"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancina</surname><given-names>RM</given-names></name><etal>et al</etal></person-group><article-title>The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent</article-title><source>Gastroenterology</source><year>2016</year><volume>150</volume><issue>5</issue><fpage>1219</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.01.032</pub-id><pub-id pub-id-type="pmid">26850495</pub-id><pub-id pub-id-type="pmcid">PMC4844071</pub-id></element-citation></ref><ref id="B165"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speliotes</surname><given-names>EK</given-names></name><etal>et al</etal></person-group><article-title>Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits</article-title><source>PLoS Genet</source><year>2011</year><volume>7</volume><issue>3</issue><elocation-id>e1001324</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1001324</pub-id><pub-id pub-id-type="pmid">21423719</pub-id><pub-id pub-id-type="pmcid">PMC3053321</pub-id></element-citation></ref><ref id="B166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nischalke</surname><given-names>HD</given-names></name><etal>et al</etal></person-group><article-title>A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease</article-title><source>J Hepatol</source><year>2014</year><volume>61</volume><issue>5</issue><fpage>1073</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2014.06.006</pub-id><pub-id pub-id-type="pmid">24946282</pub-id></element-citation></ref><ref id="B167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakamoto</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Influence of alcohol consumption and gene polymorphisms of ADH2 and ALDH2 on hepatocellular carcinoma in a Japanese population</article-title><source>Int J Cancer</source><year>2006</year><volume>118</volume><issue>6</issue><fpage>1501</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1002/ijc.21505</pub-id><pub-id pub-id-type="pmid">16187278</pub-id></element-citation></ref><ref id="B168"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abe</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Aldehyde dehydrogenase 2 polymorphism for development to hepatocellular carcinoma in East Asian alcoholic liver cirrhosis</article-title><source>J Gastroenterol Hepatol</source><year>2015</year><volume>30</volume><issue>9</issue><fpage>1376</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1111/jgh.12948</pub-id><pub-id pub-id-type="pmid">25778454</pub-id></element-citation></ref><ref id="B169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Homann</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers</article-title><source>Int J Cancer</source><year>2006</year><volume>118</volume><issue>8</issue><fpage>1998</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1002/ijc.21583</pub-id><pub-id pub-id-type="pmid">16287084</pub-id></element-citation></ref><ref id="B170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmalz</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis</article-title><source>JHEP Rep</source><year>2023</year><volume>5</volume><issue>4</issue><elocation-id>100684</elocation-id><pub-id pub-id-type="doi">10.1016/j.jhepr.2023.100684</pub-id><pub-id pub-id-type="pmid">36879887</pub-id><pub-id pub-id-type="pmcid">PMC9985032</pub-id></element-citation></ref><ref id="B171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Innes</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>The rs429358 locus in apolipoprotein E is associated with hepatocellular carcinoma in patients with cirrhosis</article-title><source>Hepatol Commun</source><year>2022</year><volume>6</volume><issue>5</issue><fpage>1213</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1002/hep4.1886</pub-id><pub-id pub-id-type="pmid">34958182</pub-id><pub-id pub-id-type="pmcid">PMC9035556</pub-id></element-citation></ref><ref id="B172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buch</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Genetic variation in <italic toggle="yes">TERT</italic> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study</article-title><source>Gut</source><year>2023</year><volume>72</volume><issue>2</issue><fpage>381</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2022-327196</pub-id><pub-id pub-id-type="pmid">35788059</pub-id><pub-id pub-id-type="pmcid">PMC9872243</pub-id></element-citation></ref><ref id="B173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stickel</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>The genetics of alcohol dependence and alcohol-related liver disease</article-title><source>J Hepatol</source><year>2017</year><volume>66</volume><issue>1</issue><fpage>195</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.08.011</pub-id><pub-id pub-id-type="pmid">27575312</pub-id></element-citation></ref><ref id="B174"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>SH</given-names></name><etal>et al</etal></person-group><article-title>Ethanol and its nonoxidative metabolites promote acute liver injury by inducing ER Stress, adipocyte death, and lipolysis</article-title><source>Cell Mol Gastroenterol Hepatol</source><year>2023</year><volume>15</volume><issue>2</issue><fpage>281</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2022.10.002</pub-id><pub-id pub-id-type="pmid">36243320</pub-id><pub-id pub-id-type="pmcid">PMC9791137</pub-id></element-citation></ref><ref id="B175"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><etal>et al</etal></person-group><article-title>Aldehyde dehydrogenase, liver disease and cancer</article-title><source>Int J Biol Sci</source><year>2020</year><volume>16</volume><issue>6</issue><fpage>921</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.7150/ijbs.42300</pub-id><pub-id pub-id-type="pmid">32140062</pub-id><pub-id pub-id-type="pmcid">PMC7053332</pub-id></element-citation></ref><ref id="B176"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polimanti</surname><given-names>R</given-names></name><name name-style="western"><surname>Gelernter</surname><given-names>J</given-names></name></person-group><article-title>ADH1B: From alcoholism, natural selection, and cancer to the human phenome</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2018</year><volume>177</volume><issue>2</issue><fpage>113</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1002/ajmg.b.32523</pub-id><pub-id pub-id-type="pmid">28349588</pub-id><pub-id pub-id-type="pmcid">PMC5617762</pub-id></element-citation></ref><ref id="B177"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charatcharoenwitthaya</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Alcohol-Associated Liver Disease: East Versus West</article-title><source>Clin Liver Dis (Hoboken)</source><year>2020</year><volume>16</volume><issue>6</issue><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1002/cld.920</pub-id><pub-id pub-id-type="pmid">33489093</pub-id><pub-id pub-id-type="pmcid">PMC7805304</pub-id></element-citation></ref><ref id="B178"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>JS</given-names></name><etal>et al</etal></person-group><article-title>ALDH2 polymorphism and alcohol-related cancers in Asians: a public health perspective</article-title><source>J Biomed Sci</source><year>2017</year><volume>24</volume><issue>1</issue><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.1186/s12929-017-0327-y</pub-id><pub-id pub-id-type="pmid">28253921</pub-id><pub-id pub-id-type="pmcid">PMC5335829</pub-id></element-citation></ref><ref id="B179"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name><etal>et al</etal></person-group><article-title>Pharmacokinetic and pharmacodynamic basis for overcoming acetaldehyde-induced adverse reaction in Asian alcoholics, heterozygous for the variant ALDH2*2 gene allele</article-title><source>Pharmacogenet Genomics</source><year>2009</year><volume>19</volume><issue>8</issue><fpage>588</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1097/FPC.0b013e32832ecf2e</pub-id><pub-id pub-id-type="pmid">19584771</pub-id></element-citation></ref><ref id="B180"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>HJ</given-names></name><etal>et al</etal></person-group><article-title>Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice</article-title><source>Hepatology</source><year>2014</year><volume>60</volume><issue>1</issue><fpage>146</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1002/hep.27036</pub-id><pub-id pub-id-type="pmid">24492981</pub-id><pub-id pub-id-type="pmcid">PMC4077916</pub-id></element-citation></ref><ref id="B181"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Alcohol inhibits T-cell glucose metabolism and hepatitis in ALDH2-deficient mice and humans: roles of acetaldehyde and glucocorticoids</article-title><source>Gut</source><year>2019</year><volume>68</volume><issue>7</issue><fpage>1311</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-316221</pub-id><pub-id pub-id-type="pmid">30121625</pub-id><pub-id pub-id-type="pmcid">PMC6582747</pub-id></element-citation></ref><ref id="B182"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szabo</surname><given-names>G</given-names></name></person-group><article-title>Women and alcoholic liver disease - warning of a silent danger</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2018</year><volume>15</volume><issue>5</issue><fpage>253</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2018.8</pub-id><pub-id pub-id-type="pmid">29443115</pub-id></element-citation></ref><ref id="B183"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delacote</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>A model to identify heavy drinkers at high risk for liver disease progression</article-title><source>Clin Gastroenterol Hepatol</source><year>2020</year><volume>18</volume><issue>10</issue><fpage>2315</fpage><lpage>2323</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2019.12.041</pub-id><pub-id pub-id-type="pmid">31931181</pub-id></element-citation></ref><ref id="B184"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singal</surname><given-names>AK</given-names></name><name name-style="western"><surname>Mathurin</surname><given-names>P</given-names></name></person-group><article-title>Diagnosis and treatment of alcohol-associated liver disease: a review</article-title><source>JAMA</source><year>2021</year><volume>326</volume><issue>2</issue><fpage>165</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.7683</pub-id><pub-id pub-id-type="pmid">34255003</pub-id></element-citation></ref><ref id="B185"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pemmasani</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Sex differences in clinical characteristics and outcomes associated with alcoholic hepatitis</article-title><source>Eur J Gastroenterol Hepatol</source><year>2023</year><volume>35</volume><issue>10</issue><fpage>1192</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000002612</pub-id><pub-id pub-id-type="pmid">37577797</pub-id></element-citation></ref><ref id="B186"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilyas</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Rising alcohol-associated liver disease-related mortality rates in the United States from 1999 to 2022</article-title><source>Hepatol Commun</source><year>2023</year><volume>7</volume><issue>7</issue><elocation-id>e00180</elocation-id><pub-id pub-id-type="doi">10.1097/HC9.0000000000000207</pub-id><pub-id pub-id-type="pmid">37314743</pub-id><pub-id pub-id-type="pmcid">PMC10270502</pub-id></element-citation></ref><ref id="B187"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rehm</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis</article-title><source>Drug Alcohol Rev</source><year>2010</year><volume>29</volume><issue>4</issue><fpage>437</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1111/j.1465-3362.2009.00153.x</pub-id><pub-id pub-id-type="pmid">20636661</pub-id></element-citation></ref><ref id="B188"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anouti</surname><given-names>A</given-names></name><name name-style="western"><surname>Mellinger</surname><given-names>JL</given-names></name></person-group><article-title>The changing epidemiology of alcohol-associated liver disease: gender, race, and risk factors</article-title><source>Semin Liver Dis</source><year>2023</year><volume>43</volume><issue>1</issue><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1055/a-2000-6680</pub-id><pub-id pub-id-type="pmid">36529138</pub-id></element-citation></ref><ref id="B189"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets</article-title><source>Hepatology</source><year>2020</year><volume>72</volume><issue>2</issue><fpage>412</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1002/hep.31031</pub-id><pub-id pub-id-type="pmid">31705800</pub-id><pub-id pub-id-type="pmcid">PMC7210045</pub-id></element-citation></ref><ref id="B190"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katsuda</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Rapid in vivo multiplexed editing (RIME) of the adult mouse liver</article-title><source>Hepatology</source><year>2023</year><volume>78</volume><issue>2</issue><fpage>486</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1002/hep.32759</pub-id><pub-id pub-id-type="pmid">36037289</pub-id><pub-id pub-id-type="pmcid">PMC11088813</pub-id></element-citation></ref><ref id="B191"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirpich</surname><given-names>IA</given-names></name><etal>et al</etal></person-group><article-title>Saturated and unsaturated dietary fats differentially modulate ethanol-induced changes in gut microbiome and metabolome in a mouse model of alcoholic liver disease</article-title><source>Am J Pathol</source><year>2016</year><volume>186</volume><issue>4</issue><fpage>765</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2015.11.017</pub-id><pub-id pub-id-type="pmid">27012191</pub-id><pub-id pub-id-type="pmcid">PMC5808146</pub-id></element-citation></ref><ref id="B192"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HS</given-names></name><etal>et al</etal></person-group><article-title>Synergistic associations of PNPLA3 I148M variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality</article-title><source>JAMA Netw Open</source><year>2022</year><volume>5</volume><issue>10</issue><elocation-id>e2234221</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.34221</pub-id><pub-id pub-id-type="pmid">36190732</pub-id><pub-id pub-id-type="pmcid">PMC9530967</pub-id></element-citation></ref><ref id="B193"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>SD</given-names></name><etal>et al</etal></person-group><article-title>Binge ethanol and liver: new molecular developments</article-title><source>Alcohol Clin Exp Res</source><year>2013</year><volume>37</volume><issue>4</issue><fpage>550</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1111/acer.12011</pub-id><pub-id pub-id-type="pmid">23347137</pub-id><pub-id pub-id-type="pmcid">PMC4831914</pub-id></element-citation></ref><ref id="B194"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Macrophage-derived MLKL in alcohol-associated liver disease: Regulation of phagocytosis</article-title><source>Hepatology</source><year>2023</year><volume>77</volume><issue>3</issue><fpage>902</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1002/hep.32612</pub-id><pub-id pub-id-type="pmid">35689613</pub-id><pub-id pub-id-type="pmcid">PMC9741663</pub-id></element-citation></ref><ref id="B195"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>STING-mediated inflammation contributes to Gao binge ethanol feeding model</article-title><source>J Cell Physiol</source><year>2022</year><volume>237</volume><issue>2</issue><fpage>1471</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1002/jcp.30606</pub-id><pub-id pub-id-type="pmid">34698390</pub-id><pub-id pub-id-type="pmcid">PMC9298121</pub-id></element-citation></ref><ref id="B196"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Loss of SQSTM1/p62 induces obesity and exacerbates alcohol-induced liver injury in aged mice</article-title><source>Cell Mol Gastroenterol Hepatol</source><year>2023</year><volume>15</volume><issue>5</issue><fpage>1027</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2023.01.016</pub-id><pub-id pub-id-type="pmid">36754207</pub-id><pub-id pub-id-type="pmcid">PMC10036741</pub-id></element-citation></ref><ref id="B197"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Hepatocyte-specific deletion of cellular repressor of E1A-stimulated genes 1 exacerbates alcohol-induced liver injury by activating stress kinases</article-title><source>Int J Biol Sci</source><year>2022</year><volume>18</volume><issue>4</issue><fpage>1612</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.7150/ijbs.67852</pub-id><pub-id pub-id-type="pmid">35280676</pub-id><pub-id pub-id-type="pmcid">PMC8898367</pub-id></element-citation></ref></ref-list><notes notes-type="version-changes"><sec sec-type="version-changes"><label>Version 1</label><title>02/01/2024</title><p>Electronic publication</p></sec></notes></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><title>Spectrum of ALD, risk factors, and comorbidities.</title><p>Almost all individuals who drink heavily (90%&#8211;95%) develop steatosis; some of them may develop more severe forms of ALD, including alcohol-associated steatohepatitis (ASH), cirrhosis, and hepatocellular carcinoma (HCC). Some patients with underlying ALD develop acute alcohol-associated hepatitis (AH) with the typical clinical syndrome jaundice. AH is often referred to as a severe form of AH that has a high short-term morality. ASH is diagnosed based on histology, while AH is diagnosed based on clinical symptoms. Many risk factors promote the development of the severe forms of ALD. Alcohol intake and comorbid factors synergistically promote the progression of ALD. Adapted with permission from <italic toggle="yes">Gastroenterology</italic> (<xref rid="B4" ref-type="bibr">4</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-134-176345-g276.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><title>Pathogenesis of and interorgan crosstalk contribution to ALD.</title><p>Excessive alcohol intake directly induces hepatocellular damage via multiple mechanisms. The crosstalk with several other organs, including brain-liver, gut-liver, and adipose-liver crosstalk, also contributes to ALD pathogenesis. Excessive alcohol consumption profoundly affects the immune system and immune cells, which also contributes to ALD progression. ABD, alcohol-associated bowel disease; AUD, alcohol use disorder; DAMP, damage-associated molecular pattern; PAMP, pathogen-associated molecular pattern; FFA, free fatty acid.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-134-176345-g277.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><title>Inflammation in ALD.</title><p>Alcohol-associated steatohepatitis (ASH) is characterized by hepatic infiltration of a large number of inflammatory cells, with predominant neutrophil and macrophage infiltration. Kupffer cells are activated at the early stage of ALD but are markedly reduced in the late stages of ALD, such as cirrhosis. ALD is also associated with infiltration of a significant number of T cells, but their subtypes and functions have not been well characterized. ALD, especially severe AH, is associated with infiltration of B cells and massive antibody deposition. The subsets and functions of inflammatory cells will be likely identified by single-cell and spatial transcriptomics and multiplex immunofluorescent staining analysis over the coming years. ASH is also associated with elevation of a large number of proinflammatory cytokines, chemokines, and adhesion molecules, which have overlapping functions and synergistically promote liver inflammation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-134-176345-g278.jpg"/></fig><table-wrap position="float" id="T6" orientation="portrait"><label>Table 6</label><caption><title>Translational research prospects of ALD</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-134-176345-g284.jpg"/></table-wrap><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5</label><caption><title>Commonly used animal models for ALD</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-134-176345-g283.jpg"/></table-wrap><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><title>Polymorphisms associated with ALD and HCC</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-134-176345-g282.jpg"/></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><title>Omics analysis of ALD in patients</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-134-176345-g281.jpg"/></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><title>Omics analysis of ALD in preclinical models</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-134-176345-g280.jpg"/></table-wrap><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Ongoing trials and druggable targets</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-134-176345-g279.jpg"/></table-wrap></floats-group></article></pmc-articleset>